#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Blunted	_
1-2	8-15	ventral	_
1-3	16-24	striatal	_
1-4	25-34	responses	_
1-5	35-37	to	_
1-6	38-49	anticipated	_
1-7	50-57	rewards	_
1-8	58-68	foreshadow	_
1-9	69-80	problematic	_
1-10	81-85	drug	_
1-11	86-89	use	_
1-12	90-92	in	_
1-13	93-108	novelty-seeking	_
1-14	109-120	adolescents	_
1-15	121-136	Novelty-seeking	_
1-16	137-147	tendencies	_
1-17	148-150	in	_
1-18	151-162	adolescents	_
1-19	163-166	may	_
1-20	167-174	promote	_
1-21	175-185	innovation	_
1-22	186-188	as	_
1-23	189-193	well	_
1-24	194-196	as	_
1-25	197-208	problematic	_
1-26	209-218	impulsive	_
1-27	219-228	behaviour	_
1-28	229-230	,	_
1-29	231-240	including	_
1-30	241-245	drug	_
1-31	246-251	abuse	_
1-32	252-253	.	_

2-1	254-262	Previous	_
2-2	263-271	research	_
2-3	272-275	has	_
2-4	276-279	not	_
2-5	280-289	clarified	_
2-6	290-297	whether	_
2-7	298-304	neural	_
2-8	305-311	hyper-	_
2-9	312-314	or	_
2-10	315-334	hypo-responsiveness	_
2-11	335-337	to	_
2-12	338-349	anticipated	_
2-13	350-357	rewards	_
2-14	358-366	promotes	_
2-15	367-380	vulnerability	_
2-16	381-383	in	_
2-17	384-389	these	_
2-18	390-401	individuals	_
2-19	402-403	.	_

3-1	404-408	Here	_
3-2	409-411	we	_
3-3	412-415	use	_
3-4	416-417	a	_
3-5	418-430	longitudinal	_
3-6	431-437	design	_
3-7	438-440	to	_
3-8	441-446	track	_
3-9	447-450	144	_
3-10	451-466	novelty-seeking	_
3-11	467-478	adolescents	_
3-12	479-481	at	_
3-13	482-485	age	_
3-14	486-488	14	_
3-15	489-492	and	_
3-16	493-495	16	_
3-17	496-498	to	_
3-18	499-508	determine	_
3-19	509-516	whether	_
3-20	517-523	neural	_
3-21	524-532	activity	_
3-22	533-535	in	_
3-23	536-544	response	_
3-24	545-547	to	_
3-25	548-559	anticipated	_
3-26	560-567	rewards	_
3-27	568-576	predicts	_
3-28	577-588	problematic	_
3-29	589-593	drug	_
3-30	594-597	use	_
3-31	598-599	.	_

4-1	600-602	We	_
4-2	603-607	find	_
4-3	608-612	that	_
4-4	613-623	diminished	_
4-5	624-628	BOLD	_
4-6	629-637	activity	_
4-7	638-640	in	_
4-8	641-651	mesolimbic	_
4-9	652-653	(	_
4-10	654-661	ventral	_
4-11	662-670	striatal	_
4-12	671-674	and	_
4-13	675-683	midbrain	_
4-14	684-685	)	_
4-15	686-689	and	_
4-16	690-700	prefrontal	_
4-17	701-709	cortical	_
4-18	710-711	(	_
4-19	712-724	dorsolateral	_
4-20	725-735	prefrontal	_
4-21	736-742	cortex	_
4-22	743-744	)	_
4-23	745-752	regions	_
4-24	753-759	during	_
4-25	760-766	reward	_
4-26	767-779	anticipation	_
4-27	780-782	at	_
4-28	783-786	age	_
4-29	787-789	14	_
4-30	790-798	predicts	_
4-31	799-810	problematic	_
4-32	811-815	drug	_
4-33	816-819	use	_
4-34	820-822	at	_
4-35	823-826	age	_
4-36	827-829	16	_
4-37	830-831	.	_

5-1	832-837	Lower	_
5-2	838-850	psychometric	_
5-3	851-868	conscientiousness	_
5-4	869-872	and	_
5-5	873-880	steeper	_
5-6	881-892	discounting	_
5-7	893-895	of	_
5-8	896-902	future	_
5-9	903-910	rewards	_
5-10	911-913	at	_
5-11	914-917	age	_
5-12	918-920	14	_
5-13	921-925	also	_
5-14	926-934	predicts	_
5-15	935-946	problematic	_
5-16	947-951	drug	_
5-17	952-955	use	_
5-18	956-958	at	_
5-19	959-962	age	_
5-20	963-965	16	_
5-21	966-967	,	_
5-22	968-971	but	_
5-23	972-975	the	_
5-24	976-982	neural	_
5-25	983-992	responses	_
5-26	993-1006	independently	_
5-27	1007-1014	predict	_
5-28	1015-1019	more	_
5-29	1020-1028	variance	_
5-30	1029-1033	than	_
5-31	1034-1046	psychometric	_
5-32	1047-1055	measures	_
5-33	1056-1057	.	_

6-1	1058-1066	Together	_
6-2	1067-1068	,	_
6-3	1069-1074	these	_
6-4	1075-1083	findings	_
6-5	1084-1091	suggest	_
6-6	1092-1096	that	_
6-7	1097-1107	diminished	_
6-8	1108-1114	neural	_
6-9	1115-1124	responses	_
6-10	1125-1127	to	_
6-11	1128-1139	anticipated	_
6-12	1140-1147	rewards	_
6-13	1148-1150	in	_
6-14	1151-1166	novelty-seeking	_
6-15	1167-1178	adolescents	_
6-16	1179-1182	may	_
6-17	1183-1191	increase	_
6-18	1192-1205	vulnerability	_
6-19	1206-1208	to	_
6-20	1209-1215	future	_
6-21	1216-1227	problematic	_
6-22	1228-1232	drug	_
6-23	1233-1236	use	_
6-24	1237-1238	.	_

7-1	1239-1243	Some	_
7-2	1244-1255	adolescents	_
7-3	1256-1260	seek	_
7-4	1261-1268	novelty	_
7-5	1269-1270	,	_
7-6	1271-1274	but	_
7-7	1275-1277	it	_
7-8	1278-1280	is	_
7-9	1281-1288	unknown	_
7-10	1289-1296	whether	_
7-11	1297-1300	the	_
7-12	1301-1306	brain	_
7-13	1307-1315	circuits	_
7-14	1316-1326	underlying	_
7-15	1327-1331	this	_
7-16	1332-1341	behaviour	_
7-17	1342-1345	can	_
7-18	1346-1348	be	_
7-19	1349-1353	used	_
7-20	1354-1356	to	_
7-21	1357-1364	predict	_
7-22	1365-1370	later	_
7-23	1371-1372	,	_
7-24	1373-1384	problematic	_
7-25	1385-1394	behaviour	_
7-26	1395-1396	.	_

8-1	1397-1401	Here	_
8-2	1402-1403	,	_
8-3	1404-1411	authors	_
8-4	1412-1416	show	_
8-5	1417-1421	that	_
8-6	1422-1432	diminished	_
8-7	1433-1440	ventral	_
8-8	1441-1449	striatal	_
8-9	1450-1453	and	_
8-10	1454-1464	prefrontal	_
8-11	1465-1473	activity	_
8-12	1474-1476	in	_
8-13	1477-1485	response	_
8-14	1486-1488	to	_
8-15	1489-1500	anticipated	_
8-16	1501-1508	rewards	_
8-17	1509-1511	at	_
8-18	1512-1515	age	_
8-19	1516-1518	14	_
8-20	1519-1521	in	_
8-21	1522-1527	these	_
8-22	1528-1539	individuals	_
8-23	1540-1548	predicts	_
8-24	1549-1560	problematic	_
8-25	1561-1565	drug	_
8-26	1566-1569	use	_
8-27	1570-1572	at	_
8-28	1573-1576	age	_
8-29	1577-1579	16	_
8-30	1580-1581	.	_

9-1	1582-1589	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-2	1590-1598	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-3	1599-1603	Data	_
9-4	1604-1607	for	_
9-5	1608-1612	this	_
9-6	1613-1618	study	_
9-7	1619-1623	came	_
9-8	1624-1628	from	_
9-9	1629-1632	the	_
9-10	1633-1639	IMAGEN	_
9-11	1640-1647	project	_
9-12	1648-1649	,	_
9-13	1650-1653	and	_
9-14	1654-1658	were	_
9-15	1659-1668	collected	_
9-16	1669-1671	at	_
9-17	1672-1680	multiple	_
9-18	1681-1686	sites	_
9-19	1687-1693	across	_
9-20	1694-1700	Europe	_
9-21	1701-1702	.	_

10-1	1703-1705	At	_
10-2	1706-1709	age	_
10-3	1710-1712	14	_
10-4	1713-1714	,	_
10-5	1715-1716	a	_
10-6	1717-1722	large	_
10-7	1723-1729	cohort	_
10-8	1730-1732	of	_
10-9	1733-1744	adolescents	_
10-10	1745-1754	completed	_
10-11	1755-1766	self-report	_
10-12	1767-1770	and	_
10-13	1771-1780	interview	_
10-14	1781-1789	measures	_
10-15	1790-1791	,	_
10-16	1792-1794	in	_
10-17	1795-1803	addition	_
10-18	1804-1806	to	_
10-19	1807-1817	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
10-20	1818-1821	and	_
10-21	1822-1826	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-22	1827-1832	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
10-23	1833-1834	.	_

11-1	1835-1843	Parental	_
11-2	1844-1850	report	_
11-3	1851-1859	measures	_
11-4	1860-1864	were	_
11-5	1865-1869	also	_
11-6	1870-1879	collected	_
11-7	1880-1883	for	_
11-8	1884-1888	some	_
11-9	1889-1899	constructs	_
11-10	1900-1901	.	_

12-1	1902-1907	Local	_
12-2	1908-1914	ethics	_
12-3	1915-1923	research	_
12-4	1924-1934	committees	_
12-5	1935-1943	approved	_
12-6	1944-1947	the	_
12-7	1948-1953	study	_
12-8	1954-1956	at	_
12-9	1957-1961	each	_
12-10	1962-1966	site	_
12-11	1967-1968	.	_

13-1	1969-1971	On	_
13-2	1972-1975	the	_
13-3	1976-1979	day	_
13-4	1980-1982	of	_
13-5	1983-1993	assessment	_
13-6	1994-1995	,	_
13-7	1996-2003	written	_
13-8	2004-2011	consent	_
13-9	2012-2015	was	_
13-10	2016-2024	obtained	_
13-11	2025-2029	from	_
13-12	2030-2034	each	_
13-13	2035-2041	parent	_
13-14	2042-2044	or	_
13-15	2045-2053	guardian	_
13-16	2054-2055	,	_
13-17	2056-2059	and	_
13-18	2060-2066	verbal	_
13-19	2067-2073	assent	_
13-20	2074-2077	was	_
13-21	2078-2086	obtained	_
13-22	2087-2091	from	_
13-23	2092-2096	each	_
13-24	2097-2107	adolescent	_
13-25	2108-2109	.	_

14-1	2110-2117	Further	_
14-2	2118-2125	details	_
14-3	2126-2128	on	_
14-4	2129-2140	recruitment	_
14-5	2141-2142	,	_
14-6	2143-2155	standardized	_
14-7	2156-2168	instructions	_
14-8	2169-2172	for	_
14-9	2173-2187	administration	_
14-10	2188-2190	of	_
14-11	2191-2203	psychometric	_
14-12	2204-2207	and	_
14-13	2208-2217	cognitive	_
14-14	2218-2229	behavioural	_
14-15	2230-2238	measures	_
14-16	2239-2240	,	_
14-17	2241-2244	and	_
14-18	2245-2250	other	_
14-19	2251-2261	procedures	_
14-20	2262-2265	are	_
14-21	2266-2275	described	_
14-22	2276-2278	in	_
14-23	2279-2282	the	_
14-24	2283-2291	Standard	_
14-25	2292-2301	Operating	_
14-26	2302-2312	Procedures	_
14-27	2313-2316	for	_
14-28	2317-2320	the	_
14-29	2321-2327	IMAGEN	_
14-30	2328-2335	project	_
14-31	2336-2337	(	_
14-32	2338-2342	http	_
14-33	2343-2344	:	_
14-34	2345-2396	//www.imagen-europe.com/en/Publications_and_SOP.php	_
14-35	2397-2398	)	_
14-36	2399-2400	.	_

15-1	2401-2409	Subjects	_
15-2	2410-2414	were	_
15-3	2415-2423	included	_
15-4	2424-2426	in	_
15-5	2427-2430	the	_
15-6	2431-2438	current	_
15-7	2439-2444	study	_
15-8	2445-2447	if	_
15-9	2448-2452	they	_
15-10	2453-2456	had	_
15-11	2457-2462	valid	_
15-12	2463-2467	data	_
15-13	2468-2471	for	_
15-14	2472-2475	all	_
15-15	2476-2484	measures	_
15-16	2485-2494	including	_
15-17	2495-2498	the	_
15-18	2499-2506	initial	_
15-19	2507-2517	assessment	_
15-20	2518-2520	at	_
15-21	2521-2524	age	_
15-22	2525-2527	14	_
15-23	2528-2531	and	_
15-24	2532-2541	follow-up	_
15-25	2542-2544	at	_
15-26	2545-2548	age	_
15-27	2549-2551	16	_
15-28	2552-2553	(	_
15-29	2554-2557	see	_
15-30	2558-2563	below	_
15-31	2564-2565	)	_
15-32	2566-2567	.	_

16-1	2568-2573	Based	_
16-2	2574-2576	on	_
16-3	2577-2582	these	_
16-4	2583-2591	criteria	_
16-5	2592-2593	,	_
16-6	2594-2596	at	_
16-7	2597-2600	the	_
16-8	2601-2605	time	_
16-9	2606-2608	of	_
16-10	2609-2617	analysis	_
16-11	2618-2619	,	_
16-12	2620-2628	complete	_
16-13	2629-2633	data	_
16-14	2634-2638	were	_
16-15	2639-2648	available	_
16-16	2649-2652	for	_
16-17	2653-2658	1,090	_
16-18	2659-2670	adolescents	_
16-19	2671-2672	.	_

17-1	2673-2680	Novelty	_
17-2	2681-2688	seeking	_
17-3	2689-2691	in	_
17-4	2692-2696	this	_
17-5	2697-2703	sample	_
17-6	2704-2707	was	_
17-7	2708-2717	initially	_
17-8	2718-2726	assessed	_
17-9	2727-2731	with	_
17-10	2732-2735	the	_
17-11	2736-2743	Novelty	_
17-12	2744-2751	Seeking	_
17-13	2752-2760	subscale	_
17-14	2761-2763	of	_
17-15	2764-2767	the	_
17-16	2768-2779	Temperament	_
17-17	2780-2783	and	_
17-18	2784-2793	Character	_
17-19	2794-2811	Inventory—Revised	_
17-20	2812-2813	.	_

18-1	2814-2818	From	_
18-2	2819-2822	the	_
18-3	2823-2831	original	_
18-4	2832-2838	sample	_
18-5	2839-2841	of	_
18-6	2842-2847	1,090	_
18-7	2848-2852	with	_
18-8	2853-2857	full	_
18-9	2858-2862	data	_
18-10	2863-2867	sets	_
18-11	2868-2869	,	_
18-12	2870-2881	individuals	_
18-13	2882-2889	scoring	_
18-14	2890-2892	in	_
18-15	2893-2896	the	_
18-16	2897-2900	top	_
18-17	2901-2905	25th	_
18-18	2906-2916	percentile	_
18-19	2917-2918	(	_
18-20	2919-2924	n=283	_
18-21	2925-2926	)	_
18-22	2927-2929	of	_
18-23	2930-2937	novelty	_
18-24	2938-2945	seeking	_
18-25	2946-2948	at	_
18-26	2949-2952	the	_
18-27	2953-2960	initial	_
18-28	2961-2971	assessment	_
18-29	2972-2974	at	_
18-30	2975-2978	age	_
18-31	2979-2981	14	_
18-32	2982-2986	were	_
18-33	2987-2995	selected	_
18-34	2996-2997	.	_

19-1	2998-3003	Based	_
19-2	3004-3006	on	_
19-3	3007-3010	the	_
19-4	3011-3019	criteria	_
19-5	3020-3029	described	_
19-6	3030-3035	below	_
19-7	3036-3037	,	_
19-8	3038-3043	these	_
19-9	3044-3052	subjects	_
19-10	3053-3057	were	_
19-11	3058-3062	then	_
19-12	3063-3073	classified	_
19-13	3074-3080	either	_
19-14	3081-3083	as	_
19-15	3084-3090	having	_
19-16	3091-3094	PDU	_
19-17	3095-3101	either	_
19-18	3102-3104	at	_
19-19	3105-3108	age	_
19-20	3109-3111	14	_
19-21	3112-3113	(	_
19-22	3114-3122	excluded	_
19-23	3123-3124	;	_
19-24	3125-3129	n=20	_
19-25	3130-3131	)	_
19-26	3132-3134	or	_
19-27	3135-3137	at	_
19-28	3138-3141	age	_
19-29	3142-3144	16	_
19-30	3145-3146	(	_
19-31	3147-3150	PDU	_
19-32	3151-3156	group	_
19-33	3157-3158	;	_
19-34	3159-3163	n=72	_
19-35	3164-3165	)	_
19-36	3166-3168	or	_
19-37	3169-3171	as	_
19-38	3172-3175	not	_
19-39	3176-3182	having	_
19-40	3183-3186	PDU	_
19-41	3187-3189	at	_
19-42	3190-3196	either	_
19-43	3197-3201	ages	_
19-44	3202-3204	14	_
19-45	3205-3207	or	_
19-46	3208-3210	16	_
19-47	3211-3212	(	_
19-48	3213-3220	control	_
19-49	3221-3226	group	_
19-50	3227-3228	;	_
19-51	3229-3234	n=191	_
19-52	3235-3236	)	_
19-53	3237-3238	.	_

20-1	3239-3244	Since	_
20-2	3245-3247	we	_
20-3	3248-3253	aimed	_
20-4	3254-3256	to	_
20-5	3257-3265	classify	_
20-6	3266-3273	whether	_
20-7	3274-3280	neural	_
20-8	3281-3288	markers	_
20-9	3289-3296	predict	_
20-10	3297-3299	or	_
20-11	3300-3306	result	_
20-12	3307-3311	from	_
20-13	3312-3316	drug	_
20-14	3317-3320	use	_
20-15	3321-3322	,	_
20-16	3323-3325	we	_
20-17	3326-3332	sought	_
20-18	3333-3335	to	_
20-19	3336-3344	directly	_
20-20	3345-3352	compare	_
20-21	3353-3356	the	_
20-22	3357-3360	PDU	_
20-23	3361-3366	group	_
20-24	3367-3369	to	_
20-25	3370-3373	the	_
20-26	3374-3381	control	_
20-27	3382-3387	group	_
20-28	3388-3395	without	_
20-29	3396-3409	statistically	_
20-30	3410-3421	significant	_
20-31	3422-3433	differences	_
20-32	3434-3436	in	_
20-33	3437-3440	PDU	_
20-34	3441-3443	at	_
20-35	3444-3447	age	_
20-36	3448-3450	14	_
20-37	3451-3452	.	_

21-1	3453-3457	Thus	_
21-2	3458-3459	,	_
21-3	3460-3462	we	_
21-4	3463-3470	further	_
21-5	3471-3478	matched	_
21-6	3479-3483	both	_
21-7	3484-3490	groups	_
21-8	3491-3495	with	_
21-9	3496-3503	respect	_
21-10	3504-3506	to	_
21-11	3507-3511	size	_
21-12	3512-3515	and	_
21-13	3516-3523	average	_
21-14	3524-3528	drug	_
21-15	3529-3535	intake	_
21-16	3536-3538	at	_
21-17	3539-3542	age	_
21-18	3543-3545	14	_
21-19	3546-3547	(	_
21-20	3548-3550	as	_
21-21	3551-3558	defined	_
21-22	3559-3561	by	_
21-23	3562-3566	each	_
21-24	3567-3577	individual	_
21-25	3578-3580	's	_
21-26	3581-3586	total	_
21-27	3587-3591	drug	_
21-28	3592-3598	intake	_
21-29	3599-3604	score	_
21-30	3605-3606	,	_
21-31	3607-3616	described	_
21-32	3617-3622	below	_
21-33	3623-3624	)	_
21-34	3625-3626	.	_

22-1	3627-3631	This	_
22-2	3632-3641	procedure	_
22-3	3642-3649	yielded	_
22-4	3650-3652	72	_
22-5	3653-3661	subjects	_
22-6	3662-3664	in	_
22-7	3665-3668	the	_
22-8	3669-3672	PDU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-9	3673-3678	group	_
22-10	3679-3682	and	_
22-11	3683-3685	72	_
22-12	3686-3693	matched	_
22-13	3694-3702	subjects	_
22-14	3703-3705	in	_
22-15	3706-3709	the	_
22-16	3710-3717	control	_
22-17	3718-3723	group	_
22-18	3724-3725	(	_
22-19	3726-3731	Table	_
22-20	3732-3733	1	_
22-21	3734-3735	;	_
22-22	3736-3739	Fig	_
22-23	3740-3741	.	_

23-1	3742-3743	5	_
23-2	3744-3745	)	_
23-3	3746-3747	.	_

24-1	3748-3751	PDU	_
24-2	3752-3760	criteria	_
24-3	3761-3764	PDU	_
24-4	3765-3768	was	_
24-5	3769-3782	operationally	_
24-6	3783-3790	defined	_
24-7	3791-3796	based	_
24-8	3797-3799	on	_
24-9	3800-3808	measures	_
24-10	3809-3818	according	_
24-11	3819-3821	to	_
24-12	3822-3825	the	_
24-13	3826-3834	European	_
24-14	3835-3841	School	_
24-15	3842-3848	Survey	_
24-16	3849-3856	Project	_
24-17	3857-3859	on	_
24-18	3860-3867	Alcohol	_
24-19	3868-3871	and	_
24-20	3872-3877	Other	_
24-21	3878-3883	Drugs	_
24-22	3884-3885	(	_
24-23	3886-3891	ESPAD	_
24-24	3892-3893	)	_
24-25	3894-3895	.	_

25-1	3896-3902	Unlike	_
25-2	3903-3914	traditional	_
25-3	3915-3923	clinical	_
25-4	3924-3935	instruments	_
25-5	3936-3937	(	_
25-6	3938-3941	for	_
25-7	3942-3949	example	_
25-8	3950-3951	,	_
25-9	3952-3955	the	_
25-10	3956-3966	Diagnostic	_
25-11	3967-3970	and	_
25-12	3971-3982	Statistical	_
25-13	3983-3989	Manual	_
25-14	3990-3992	of	_
25-15	3993-3999	Mental	_
25-16	4000-4009	Disorders	_
25-17	4010-4011	,	_
25-18	4012-4019	version	_
25-19	4020-4021	5	_
25-20	4022-4023	)	_
25-21	4024-4029	these	_
25-22	4030-4038	measures	_
25-23	4039-4047	provided	_
25-24	4048-4049	a	_
25-25	4050-4061	preclinical	_
25-26	4062-4067	index	_
25-27	4068-4070	of	_
25-28	4071-4075	drug	_
25-29	4076-4079	use	_
25-30	4080-4082	at	_
25-31	4083-4087	ages	_
25-32	4088-4090	14	_
25-33	4091-4094	and	_
25-34	4095-4097	16	_
25-35	4098-4099	.	_

26-1	4100-4104	Thus	_
26-2	4105-4106	,	_
26-3	4107-4113	cutoff	_
26-4	4114-4122	criteria	_
26-5	4123-4126	for	_
26-6	4127-4130	PDU	_
26-7	4131-4135	were	_
26-8	4136-4143	defined	_
26-9	4144-4146	to	_
26-10	4147-4154	capture	_
26-11	4155-4166	problematic	_
26-12	4167-4170	use	_
26-13	4171-4173	of	_
26-14	4174-4181	various	_
26-15	4182-4187	legal	_
26-16	4188-4190	or	_
26-17	4191-4198	illicit	_
26-18	4199-4204	drugs	_
26-19	4205-4206	.	_

27-1	4207-4211	With	_
27-2	4212-4219	respect	_
27-3	4220-4222	to	_
27-4	4223-4228	legal	_
27-5	4229-4234	drugs	_
27-6	4235-4236	(	_
27-7	4237-4244	alcohol	_
27-8	4245-4248	and	_
27-9	4249-4259	cigarettes	_
27-10	4260-4261	)	_
27-11	4262-4263	,	_
27-12	4264-4265	a	_
27-13	4266-4275	threshold	_
27-14	4276-4279	was	_
27-15	4280-4283	set	_
27-16	4284-4288	that	_
27-17	4289-4298	indicated	_
27-18	4299-4304	daily	_
27-19	4305-4308	use	_
27-20	4309-4310	.	_

28-1	4311-4313	In	_
28-2	4314-4324	particular	_
28-3	4325-4326	,	_
28-4	4327-4328	a	_
28-5	4329-4334	score	_
28-6	4335-4337	of	_
28-7	4338-4339	3	_
28-8	4340-4342	or	_
28-9	4343-4349	higher	_
28-10	4350-4352	on	_
28-11	4353-4360	smoking	_
28-12	4361-4362	(	_
28-13	4363-4364	0	_
28-14	4365-4366	:	_
28-15	4367-4368	‘	_
28-16	4369-4372	Not	_
28-17	4373-4375	at	_
28-18	4376-4379	all	_
28-19	4380-4381	'	_
28-20	4382-4383	,	_
28-21	4384-4385	1	_
28-22	4386-4387	:	_
28-23	4388-4389	‘	_
28-24	4390-4394	Less	_
28-25	4395-4399	than	_
28-26	4400-4401	1	_
28-27	4402-4411	cigarette	_
28-28	4412-4415	per	_
28-29	4416-4420	week	_
28-30	4421-4422	'	_
28-31	4423-4424	,	_
28-32	4425-4426	2	_
28-33	4427-4428	:	_
28-34	4429-4430	‘	_
28-35	4431-4435	Less	_
28-36	4436-4440	than	_
28-37	4441-4442	1	_
28-38	4443-4452	cigarette	_
28-39	4453-4456	per	_
28-40	4457-4460	day	_
28-41	4461-4462	'	_
28-42	4463-4464	,	_
28-43	4465-4466	3	_
28-44	4467-4468	:	_
28-45	4469-4470	‘	_
28-46	4471-4474	1–5	_
28-47	4475-4485	cigarettes	_
28-48	4486-4489	per	_
28-49	4490-4493	day	_
28-50	4494-4495	'	_
28-51	4496-4497	,	_
28-52	4498-4499	4	_
28-53	4500-4501	:	_
28-54	4502-4503	‘	_
28-55	4504-4508	6–10	_
28-56	4509-4519	cigarettes	_
28-57	4520-4523	per	_
28-58	4524-4527	day	_
28-59	4528-4529	'	_
28-60	4530-4531	,	_
28-61	4532-4533	5	_
28-62	4534-4535	:	_
28-63	4536-4537	‘	_
28-64	4538-4543	11–20	_
28-65	4544-4554	cigarettes	_
28-66	4555-4558	per	_
28-67	4559-4562	day	_
28-68	4563-4564	'	_
28-69	4565-4566	,	_
28-70	4567-4568	6	_
28-71	4569-4570	:	_
28-72	4571-4572	‘	_
28-73	4573-4577	More	_
28-74	4578-4582	than	_
28-75	4583-4585	20	_
28-76	4586-4596	cigarettes	_
28-77	4597-4600	per	_
28-78	4601-4604	day	_
28-79	4605-4606	'	_
28-80	4607-4608	)	_
28-81	4609-4612	and	_
28-82	4613-4614	a	_
28-83	4615-4620	score	_
28-84	4621-4623	of	_
28-85	4624-4625	5	_
28-86	4626-4628	or	_
28-87	4629-4635	higher	_
28-88	4636-4638	on	_
28-89	4639-4646	alcohol	_
28-90	4647-4658	consumption	_
28-91	4659-4660	(	_
28-92	4661-4662	0	_
28-93	4663-4664	:	_
28-94	4665-4666	‘	_
28-95	4667-4668	0	_
28-96	4669-4675	drinks	_
28-97	4676-4679	per	_
28-98	4680-4685	month	_
28-99	4686-4687	'	_
28-100	4688-4689	,	_
28-101	4690-4691	1	_
28-102	4692-4693	:	_
28-103	4694-4695	‘	_
28-104	4696-4699	1–2	_
28-105	4700-4706	drinks	_
28-106	4707-4710	per	_
28-107	4711-4716	month	_
28-108	4717-4718	'	_
28-109	4719-4720	,	_
28-110	4721-4722	2	_
28-111	4723-4724	:	_
28-112	4725-4726	‘	_
28-113	4727-4730	3–5	_
28-114	4731-4737	drinks	_
28-115	4738-4741	per	_
28-116	4742-4747	month	_
28-117	4748-4749	'	_
28-118	4750-4751	,	_
28-119	4752-4753	3	_
28-120	4754-4755	:	_
28-121	4756-4757	‘	_
28-122	4758-4761	6–9	_
28-123	4762-4763	'	_
28-124	4764-4765	,	_
28-125	4766-4767	4	_
28-126	4768-4769	:	_
28-127	4770-4771	‘	_
28-128	4772-4777	10–19	_
28-129	4778-4779	'	_
28-130	4780-4781	,	_
28-131	4782-4783	5	_
28-132	4784-4785	:	_
28-133	4786-4787	‘	_
28-134	4788-4793	20–39	_
28-135	4794-4795	'	_
28-136	4796-4799	and	_
28-137	4800-4801	6	_
28-138	4802-4803	:	_
28-139	4804-4805	‘	_
28-140	4806-4808	40	_
28-141	4809-4811	or	_
28-142	4812-4816	more	_
28-143	4817-4818	'	_
28-144	4819-4820	)	_
28-145	4821-4827	within	_
28-146	4828-4831	the	_
28-147	4832-4836	last	_
28-148	4837-4839	30	_
28-149	4840-4844	days	_
28-150	4845-4849	were	_
28-151	4850-4857	defined	_
28-152	4858-4860	as	_
28-153	4861-4864	PDU	_
28-154	4865-4866	.	_

29-1	4867-4871	With	_
29-2	4872-4879	respect	_
29-3	4880-4882	to	_
29-4	4883-4890	illicit	_
29-5	4891-4896	drugs	_
29-6	4897-4898	,	_
29-7	4899-4902	PDU	_
29-8	4903-4913	thresholds	_
29-9	4914-4918	were	_
29-10	4919-4924	based	_
29-11	4925-4927	on	_
29-12	4928-4936	lifetime	_
29-13	4937-4940	use	_
29-14	4941-4942	.	_

30-1	4943-4948	Apart	_
30-2	4949-4953	from	_
30-3	4954-4962	cannabis	_
30-4	4963-4964	,	_
30-5	4965-4970	where	_
30-6	4971-4974	the	_
30-7	4975-4984	threshold	_
30-8	4985-4988	was	_
30-9	4989-4992	set	_
30-10	4993-4995	to	_
30-11	4996-4998	39	_
30-12	4999-5007	lifetime	_
30-13	5008-5017	occasions	_
30-14	5018-5019	,	_
30-15	5020-5023	the	_
30-16	5024-5033	threshold	_
30-17	5034-5037	for	_
30-18	5038-5043	other	_
30-19	5044-5049	drugs	_
30-20	5050-5051	(	_
30-21	5052-5056	glue	_
30-22	5057-5058	,	_
30-23	5059-5072	tranquilizers	_
30-24	5073-5074	,	_
30-25	5075-5086	amphetamine	_
30-26	5087-5088	,	_
30-27	5089-5097	lysergic	_
30-28	5098-5102	acid	_
30-29	5103-5115	diethylamide	_
30-30	5116-5117	(	_
30-31	5118-5121	LSD	_
30-32	5122-5123	)	_
30-33	5124-5125	,	_
30-34	5126-5140	hallucinogenic	_
30-35	5141-5150	mushrooms	_
30-36	5151-5152	,	_
30-37	5153-5156	3,4	_
30-38	5157-5186	methylenedioxymethamphetamine	_
30-39	5187-5188	(	_
30-40	5189-5193	MDMA	_
30-41	5194-5195	)	_
30-42	5196-5197	,	_
30-43	5198-5206	ketamine	_
30-44	5207-5209	or	_
30-45	5210-5216	liquid	_
30-46	5217-5224	ecstasy	_
30-47	5225-5226	)	_
30-48	5227-5230	was	_
30-49	5231-5234	set	_
30-50	5235-5237	to	_
30-51	5238-5241	3–5	_
30-52	5242-5251	occasions	_
30-53	5252-5254	or	_
30-54	5255-5259	more	_
30-55	5260-5261	.	_

31-1	5262-5265	Use	_
31-2	5266-5268	of	_
31-3	5269-5270	a	_
31-4	5271-5279	lifetime	_
31-5	5280-5285	score	_
31-6	5286-5289	and	_
31-7	5290-5299	therefore	_
31-8	5300-5301	a	_
31-9	5302-5307	lower	_
31-10	5308-5317	threshold	_
31-11	5318-5327	criterion	_
31-12	5328-5331	for	_
31-13	5332-5337	these	_
31-14	5338-5343	drugs	_
31-15	5344-5347	was	_
31-16	5348-5357	justified	_
31-17	5358-5360	by	_
31-18	5361-5364	the	_
31-19	5365-5369	fact	_
31-20	5370-5374	that	_
31-21	5375-5380	early	_
31-22	5381-5384	use	_
31-23	5385-5387	of	_
31-24	5388-5393	these	_
31-25	5394-5399	drugs	_
31-26	5400-5408	robustly	_
31-27	5409-5417	predicts	_
31-28	5418-5421	PDU	_
31-29	5422-5427	later	_
31-30	5428-5430	in	_
31-31	5431-5435	life	_
31-32	5436-5437	(	_
31-33	5438-5441	for	_
31-34	5442-5449	example	_
31-35	5450-5451	,	_
31-36	5452-5453	a	_
31-37	5454-5463	threefold	_
31-38	5464-5468	risk	_
31-39	5469-5474	after	_
31-40	5475-5480	early	_
31-41	5481-5489	cannabis	_
31-42	5490-5493	use	_
31-43	5494-5495	)	_
31-44	5496-5497	.	_

32-1	5498-5505	Finally	_
32-2	5506-5507	,	_
32-3	5508-5511	the	_
32-4	5512-5521	threshold	_
32-5	5522-5525	for	_
32-6	5526-5533	illicit	_
32-7	5534-5539	drugs	_
32-8	5540-5541	(	_
32-9	5542-5545	for	_
32-10	5546-5553	example	_
32-11	5554-5555	,	_
32-12	5556-5561	crack	_
32-13	5562-5563	,	_
32-14	5564-5571	cocaine	_
32-15	5572-5573	,	_
32-16	5574-5580	heroin	_
32-17	5581-5584	and	_
32-18	5585-5594	narcotics	_
32-19	5595-5596	)	_
32-20	5597-5600	was	_
32-21	5601-5604	set	_
32-22	5605-5607	to	_
32-23	5608-5611	1–2	_
32-24	5612-5614	or	_
32-25	5615-5619	more	_
32-26	5620-5629	occasions	_
32-27	5630-5631	(	_
32-28	5632-5645	Supplementary	_
32-29	5646-5650	Figs	_
32-30	5651-5652	5	_
32-31	5653-5656	and	_
32-32	5657-5658	6	_
32-33	5659-5665	depict	_
32-34	5666-5669	the	_
32-35	5670-5682	distribution	_
32-36	5683-5685	of	_
32-37	5686-5692	scores	_
32-38	5693-5696	for	_
32-39	5697-5701	both	_
32-40	5702-5708	groups	_
32-41	5709-5711	at	_
32-42	5712-5715	age	_
32-43	5716-5718	14	_
32-44	5719-5722	and	_
32-45	5723-5725	16	_
32-46	5726-5727	,	_
32-47	5728-5731	and	_
32-48	5732-5739	cutoffs	_
32-49	5740-5743	for	_
32-50	5744-5748	each	_
32-51	5749-5758	substance	_
32-52	5759-5760	)	_
32-53	5761-5762	.	_

33-1	5763-5767	None	_
33-2	5768-5770	of	_
33-3	5771-5774	the	_
33-4	5775-5783	subjects	_
33-5	5784-5786	in	_
33-6	5787-5793	either	_
33-7	5794-5799	group	_
33-8	5800-5804	fell	_
33-9	5805-5810	above	_
33-10	5811-5814	the	_
33-11	5815-5824	threshold	_
33-12	5825-5828	for	_
33-13	5829-5832	use	_
33-14	5833-5835	of	_
33-15	5836-5839	any	_
33-16	5840-5849	substance	_
33-17	5850-5852	at	_
33-18	5853-5856	age	_
33-19	5857-5859	14	_
33-20	5860-5861	(	_
33-21	5862-5875	Supplementary	_
33-22	5876-5879	Fig	_
33-23	5880-5881	.	_

34-1	5882-5883	5	_
34-2	5884-5885	)	_
34-3	5886-5887	.	_

35-1	5888-5899	Furthermore	_
35-2	5900-5901	,	_
35-3	5902-5906	most	_
35-4	5907-5915	subjects	_
35-5	5916-5920	were	_
35-6	5921-5931	classified	_
35-7	5932-5934	as	_
35-8	5935-5938	PDU	_
35-9	5939-5941	by	_
35-10	5942-5947	means	_
35-11	5948-5950	of	_
35-12	5951-5956	daily	_
35-13	5957-5966	cigarette	_
35-14	5967-5970	use	_
35-15	5971-5972	,	_
35-16	5973-5981	followed	_
35-17	5982-5984	by	_
35-18	5985-5992	alcohol	_
35-19	5993-5996	and	_
35-20	5997-6010	cannabis—only	_
35-21	6011-6012	a	_
35-22	6013-6016	few	_
35-23	6017-6021	were	_
35-24	6022-6032	classified	_
35-25	6033-6035	as	_
35-26	6036-6039	PDU	_
35-27	6040-6045	based	_
35-28	6046-6048	on	_
35-29	6049-6054	their	_
35-30	6055-6058	use	_
35-31	6059-6061	of	_
35-32	6062-6067	other	_
35-33	6068-6075	illicit	_
35-34	6076-6081	drugs	_
35-35	6082-6083	(	_
35-36	6084-6087	for	_
35-37	6088-6095	example	_
35-38	6096-6097	,	_
35-39	6098-6102	MDMA	_
35-40	6103-6106	and	_
35-41	6107-6119	amphetamines	_
35-42	6120-6121	;	_
35-43	6122-6135	Supplementary	_
35-44	6136-6140	Figs	_
35-45	6141-6142	5	_
35-46	6143-6146	and	_
35-47	6147-6148	6	_
35-48	6149-6150	)	_
35-49	6151-6152	.	_

36-1	6153-6164	Personality	_
36-2	6165-6168	and	_
36-3	6169-6184	psychopathology	_
36-4	6185-6193	measures	_
36-5	6194-6201	Novelty	_
36-6	6202-6209	seeking	_
36-7	6210-6213	was	_
36-8	6214-6222	assessed	_
36-9	6223-6228	using	_
36-10	6229-6230	a	_
36-11	6231-6239	subscale	_
36-12	6240-6242	of	_
36-13	6243-6246	the	_
36-14	6247-6258	Temperament	_
36-15	6259-6262	and	http://maven.renci.org/NeuroBridge/neurobridge#TemperamentandCharacterInventoryScale
36-16	6263-6272	Character	http://maven.renci.org/NeuroBridge/neurobridge#TemperamentandCharacterInventoryScale
36-17	6273-6290	Inventory—Revised	http://maven.renci.org/NeuroBridge/neurobridge#TemperamentandCharacterInventoryScale
36-18	6291-6292	.	_

37-1	6293-6303	Dimensions	_
37-2	6304-6306	of	_
37-3	6307-6318	personality	_
37-4	6319-6323	were	_
37-5	6324-6332	assessed	_
37-6	6333-6338	using	_
37-7	6339-6342	the	_
37-8	6343-6350	60-item	_
37-9	6351-6384	Neuroticism-Extraversion-Openness	_
37-10	6385-6396	Five-Factor	_
37-11	6397-6406	Inventory	_
37-12	6407-6408	,	_
37-13	6409-6414	which	_
37-14	6415-6422	indexes	_
37-15	6423-6433	dimensions	_
37-16	6434-6436	of	_
37-17	6437-6449	Extraversion	_
37-18	6450-6451	,	_
37-19	6452-6465	Agreeableness	_
37-20	6466-6467	,	_
37-21	6468-6485	Conscientiousness	_
37-22	6486-6487	,	_
37-23	6488-6499	Neuroticism	_
37-24	6500-6501	,	_
37-25	6502-6505	and	_
37-26	6506-6514	Openness	_
37-27	6515-6517	to	_
37-28	6518-6528	Experience	_
37-29	6529-6530	,	_
37-30	6531-6533	as	_
37-31	6534-6543	described	_
37-32	6544-6546	by	_
37-33	6547-6550	the	_
37-34	6551-6562	Five-Factor	_
37-35	6563-6568	Model	_
37-36	6569-6571	of	_
37-37	6572-6583	personality	_
37-38	6584-6585	.	_

38-1	6586-6596	Adolescent	_
38-2	6597-6608	psychiatric	_
38-3	6609-6617	symptoms	_
38-4	6618-6621	and	_
38-5	6622-6627	their	_
38-6	6628-6634	impact	_
38-7	6635-6639	were	_
38-8	6640-6648	assessed	_
38-9	6649-6653	with	_
38-10	6654-6657	the	_
38-11	6658-6669	Development	_
38-12	6670-6673	and	_
38-13	6674-6684	Well-Being	_
38-14	6685-6695	Assessment	_
38-15	6696-6697	,	_
38-16	6698-6703	which	_
38-17	6704-6713	generates	_
38-18	6714-6727	probabilities	_
38-19	6728-6732	that	_
38-20	6733-6744	individuals	_
38-21	6745-6752	qualify	_
38-22	6753-6756	for	_
38-23	6757-6767	Diagnostic	_
38-24	6768-6771	and	_
38-25	6772-6783	Statistical	_
38-26	6784-6790	Manual	_
38-27	6791-6793	of	_
38-28	6794-6800	Mental	_
38-29	6801-6810	Disorders	_
38-30	6811-6812	(	_
38-31	6813-6820	version	_
38-32	6821-6822	4	_
38-33	6823-6824	)	_
38-34	6825-6836	psychiatric	_
38-35	6837-6846	diagnoses	_
38-36	6847-6848	.	_

39-1	6849-6858	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
39-2	6859-6867	measures	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
39-3	6868-6876	Subjects	_
39-4	6877-6886	completed	_
39-5	6887-6888	a	_
39-6	6889-6896	version	_
39-7	6897-6899	of	_
39-8	6900-6903	the	_
39-9	6904-6912	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
39-10	6913-6925	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
39-11	6926-6931	Scale	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
39-12	6932-6935	for	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
39-13	6936-6947	Children-IV	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
39-14	6948-6949	,	_
39-15	6950-6955	which	_
39-16	6956-6964	included	_
39-17	6965-6968	the	_
39-18	6969-6979	Perceptual	_
39-19	6980-6989	Reasoning	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
39-20	6990-6991	,	_
39-21	6992-6998	Matrix	_
39-22	6999-7008	Reasoning	_
39-23	7009-7012	and	_
39-24	7013-7025	Similarities	_
39-25	7026-7027	,	_
39-26	7028-7031	and	_
39-27	7032-7042	Vocabulary	_
39-28	7043-7049	scales	http://maven.renci.org/NeuroBridge/neurobridge#Scale
39-29	7050-7052	to	_
39-30	7053-7058	index	_
39-31	7059-7071	intelligence	_
39-32	7072-7073	.	_

40-1	7074-7077	The	_
40-2	7078-7093	Monetary-Choice	_
40-3	7094-7107	Questionnaire	_
40-4	7108-7109	(	_
40-5	7110-7113	MCQ	_
40-6	7114-7115	)	_
40-7	7116-7119	was	_
40-8	7120-7132	administered	_
40-9	7133-7135	to	_
40-10	7136-7142	assess	_
40-11	7143-7148	delay	_
40-12	7149-7163	discounting—or	_
40-13	7164-7174	individual	_
40-14	7175-7186	differences	_
40-15	7187-7189	in	_
40-16	7190-7193	the	_
40-17	7194-7202	tendency	_
40-18	7203-7205	to	_
40-19	7206-7212	choose	_
40-20	7213-7219	sooner	_
40-21	7220-7223	but	_
40-22	7224-7231	smaller	_
40-23	7232-7236	over	_
40-24	7237-7242	later	_
40-25	7243-7246	but	_
40-26	7247-7253	larger	_
40-27	7254-7261	rewards	_
40-28	7262-7263	(	_
40-29	7264-7268	this	_
40-30	7269-7274	index	_
40-31	7275-7285	correlates	_
40-32	7286-7290	well	_
40-33	7291-7295	with	_
40-34	7296-7300	more	_
40-35	7301-7308	precise	_
40-36	7309-7312	but	_
40-37	7313-7317	also	_
40-38	7318-7322	more	_
40-39	7323-7337	time-consuming	_
40-40	7338-7346	measures	_
40-41	7347-7348	)	_
40-42	7349-7350	.	_

41-1	7351-7359	Subjects	_
41-2	7360-7364	also	_
41-3	7365-7374	completed	_
41-4	7375-7378	the	_
41-5	7379-7388	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
41-6	7389-7397	Gambling	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
41-7	7398-7402	Task	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
41-8	7403-7404	(	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
41-9	7405-7408	CGT	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
41-10	7409-7410	)	http://maven.renci.org/NeuroBridge/neurobridge#PathologicalGambling
41-11	7411-7412	,	_
41-12	7413-7415	as	_
41-13	7416-7417	a	_
41-14	7418-7429	behavioural	_
41-15	7430-7437	measure	_
41-16	7438-7440	of	_
41-17	7441-7445	risk	_
41-18	7446-7453	seeking	_
41-19	7454-7455	.	_

42-1	7456-7468	Demographics	_
42-2	7469-7472	The	_
42-3	7473-7480	Puberty	http://maven.renci.org/NeuroBridge/neurobridge#MixedDisorderofPsychologicalDevelopment
42-4	7481-7492	Development	http://maven.renci.org/NeuroBridge/neurobridge#MixedDisorderofPsychologicalDevelopment
42-5	7493-7498	Scale	http://maven.renci.org/NeuroBridge/neurobridge#MixedDisorderofPsychologicalDevelopment
42-6	7499-7507	assessed	_
42-7	7508-7512	each	_
42-8	7513-7520	subject	_
42-9	7521-7523	's	_
42-10	7524-7532	pubertal	_
42-11	7533-7539	status	_
42-12	7540-7541	.	_

43-1	7542-7555	Socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#SocioEconomicStatus
43-2	7556-7562	status	_
43-3	7563-7569	scores	_
43-4	7570-7574	were	_
43-5	7575-7583	assessed	_
43-6	7584-7589	using	_
43-7	7590-7591	a	_
43-8	7592-7601	composite	_
43-9	7602-7607	score	_
43-10	7608-7612	that	_
43-11	7613-7620	indexed	_
43-12	7621-7624	the	_
43-13	7625-7633	weighted	_
43-14	7634-7637	sum	_
43-15	7638-7640	of	_
43-16	7641-7644	the	_
43-17	7645-7654	following	_
43-18	7655-7664	variables	_
43-19	7665-7666	:	_
43-20	7667-7673	Mother	_
43-21	7674-7676	's	_
43-22	7677-7686	Education	_
43-23	7687-7692	Score	_
43-24	7693-7694	,	_
43-25	7695-7701	Father	_
43-26	7702-7704	's	_
43-27	7705-7714	Education	_
43-28	7715-7720	Score	_
43-29	7721-7722	,	_
43-30	7723-7729	Family	_
43-31	7730-7736	Stress	_
43-32	7737-7749	Unemployment	_
43-33	7750-7755	Score	_
43-34	7756-7757	,	_
43-35	7758-7767	Financial	_
43-36	7768-7780	Difficulties	_
43-37	7781-7786	Score	_
43-38	7787-7788	,	_
43-39	7789-7793	Home	_
43-40	7794-7804	Inadequacy	_
43-41	7805-7810	Score	_
43-42	7811-7812	,	_
43-43	7813-7825	Neighborhood	_
43-44	7826-7831	Score	_
43-45	7832-7833	,	_
43-46	7834-7843	Financial	_
43-47	7844-7850	Crisis	_
43-48	7851-7856	Score	_
43-49	7857-7858	,	_
43-50	7859-7865	Mother	_
43-51	7866-7874	Employed	_
43-52	7875-7880	Score	_
43-53	7881-7882	,	_
43-54	7883-7889	Father	_
43-55	7890-7898	Employed	_
43-56	7899-7904	Score	_
43-57	7905-7906	.	_

44-1	7907-7915	Negative	_
44-2	7916-7917	(	_
44-3	7918-7922	that	_
44-4	7923-7925	is	_
44-5	7926-7927	,	_
44-6	7928-7932	high	_
44-7	7933-7937	risk	_
44-8	7938-7939	)	_
44-9	7940-7946	scores	_
44-10	7947-7951	were	_
44-11	7952-7965	reverse-coded	_
44-12	7966-7967	.	_

45-1	7968-7978	Functional	_
45-2	7979-7991	neuroimaging	_
45-3	7992-7996	data	_
45-4	7997-8008	acquisition	_
45-5	8009-8012	and	_
45-6	8013-8021	analysis	_
45-7	8022-8025	The	_
45-8	8026-8030	task	_
45-9	8031-8035	used	_
45-10	8036-8038	to	_
45-11	8039-8044	probe	_
45-12	8045-8051	neural	_
45-13	8052-8060	activity	_
45-14	8061-8067	during	_
45-15	8068-8074	reward	_
45-16	8075-8087	anticipation	_
45-17	8088-8091	was	_
45-18	8092-8093	a	_
45-19	8094-8102	modified	_
45-20	8103-8110	version	_
45-21	8111-8113	of	_
45-22	8114-8117	the	_
45-23	8118-8121	MID	_
45-24	8122-8126	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
45-25	8127-8128	,	_
45-26	8129-8134	which	_
45-27	8135-8143	required	_
45-28	8144-8152	subjects	_
45-29	8153-8155	to	_
45-30	8156-8163	respond	_
45-31	8164-8169	after	_
45-32	8170-8176	seeing	_
45-33	8177-8178	a	_
45-34	8179-8182	cue	_
45-35	8183-8185	to	_
45-36	8186-8187	a	_
45-37	8188-8195	briefly	_
45-38	8196-8205	presented	_
45-39	8206-8212	target	_
45-40	8213-8215	by	_
45-41	8216-8224	pressing	_
45-42	8225-8228	one	_
45-43	8229-8231	of	_
45-44	8232-8235	two	_
45-45	8236-8243	buttons	_
45-46	8244-8246	as	_
45-47	8247-8254	rapidly	_
45-48	8255-8257	as	_
45-49	8258-8266	possible	_
45-50	8267-8269	to	_
45-51	8270-8278	indicate	_
45-52	8279-8286	whether	_
45-53	8287-8290	the	_
45-54	8291-8297	target	_
45-55	8298-8306	appeared	_
45-56	8307-8309	on	_
45-57	8310-8313	the	_
45-58	8314-8318	left	_
45-59	8319-8321	or	_
45-60	8322-8325	the	_
45-61	8326-8331	right	_
45-62	8332-8336	side	_
45-63	8337-8339	of	_
45-64	8340-8343	the	_
45-65	8344-8350	screen	_
45-66	8351-8352	(	_
45-67	8353-8356	Fig	_
45-68	8357-8358	.	_

46-1	8359-8360	6	_
46-2	8361-8362	)	_
46-3	8363-8364	.	_

47-1	8365-8367	If	_
47-2	8368-8376	subjects	_
47-3	8377-8386	responded	_
47-4	8387-8392	while	_
47-5	8393-8396	the	_
47-6	8397-8403	target	_
47-7	8404-8407	was	_
47-8	8408-8410	on	_
47-9	8411-8414	the	_
47-10	8415-8421	screen	_
47-11	8422-8423	,	_
47-12	8424-8428	they	_
47-13	8429-8437	received	_
47-14	8438-8444	points	_
47-15	8445-8446	,	_
47-16	8447-8450	but	_
47-17	8451-8453	if	_
47-18	8454-8458	they	_
47-19	8459-8468	responded	_
47-20	8469-8475	before	_
47-21	8476-8478	or	_
47-22	8479-8484	after	_
47-23	8485-8488	the	_
47-24	8489-8495	target	_
47-25	8496-8498	's	_
47-26	8499-8512	disappearance	_
47-27	8513-8514	,	_
47-28	8515-8519	they	_
47-29	8520-8528	received	_
47-30	8529-8531	no	_
47-31	8532-8538	points	_
47-32	8539-8540	.	_

48-1	8541-8545	Cues	_
48-2	8546-8555	signalled	_
48-3	8556-8560	each	_
48-4	8561-8566	trial	_
48-5	8567-8569	's	_
48-6	8570-8575	onset	_
48-7	8576-8577	,	_
48-8	8578-8581	and	_
48-9	8582-8590	reliably	_
48-10	8591-8600	indicated	_
48-11	8601-8604	the	_
48-12	8605-8613	position	_
48-13	8614-8616	of	_
48-14	8617-8620	the	_
48-15	8621-8627	target	_
48-16	8628-8630	as	_
48-17	8631-8635	well	_
48-18	8636-8638	as	_
48-19	8639-8642	the	_
48-20	8643-8649	number	_
48-21	8650-8652	of	_
48-22	8653-8659	points	_
48-23	8660-8662	to	_
48-24	8663-8665	be	_
48-25	8666-8673	awarded	_
48-26	8674-8677	for	_
48-27	8678-8679	a	_
48-28	8680-8690	successful	_
48-29	8691-8699	response	_
48-30	8700-8701	.	_

49-1	8702-8706	Cues	_
49-2	8707-8711	took	_
49-3	8712-8715	one	_
49-4	8716-8718	of	_
49-5	8719-8724	three	_
49-6	8725-8730	forms	_
49-7	8731-8732	:	_
49-8	8733-8734	a	_
49-9	8735-8743	triangle	_
49-10	8744-8753	indicated	_
49-11	8754-8756	no	_
49-12	8757-8763	points	_
49-13	8764-8765	(	_
49-14	8766-8767	‘	_
49-15	8768-8770	No	_
49-16	8771-8775	Gain	_
49-17	8776-8777	'	_
49-18	8778-8779	)	_
49-19	8780-8781	,	_
49-20	8782-8783	a	_
49-21	8784-8790	circle	_
49-22	8791-8795	with	_
49-23	8796-8799	one	_
49-24	8800-8804	line	_
49-25	8805-8814	indicated	_
49-26	8815-8816	2	_
49-27	8817-8823	points	_
49-28	8824-8825	(	_
49-29	8826-8827	‘	_
49-30	8828-8833	Small	_
49-31	8834-8838	Gain	_
49-32	8839-8840	'	_
49-33	8841-8842	)	_
49-34	8843-8846	and	_
49-35	8847-8848	a	_
49-36	8849-8855	circle	_
49-37	8856-8860	with	_
49-38	8861-8866	three	_
49-39	8867-8872	lines	_
49-40	8873-8882	indicated	_
49-41	8883-8885	10	_
49-42	8886-8892	points	_
49-43	8893-8894	(	_
49-44	8895-8896	‘	_
49-45	8897-8902	Large	_
49-46	8903-8907	Gain	_
49-47	8908-8909	'	_
49-48	8910-8911	)	_
49-49	8912-8914	at	_
49-50	8915-8920	stake	_
49-51	8921-8922	.	_

50-1	8923-8934	Behavioural	_
50-2	8935-8939	data	_
50-3	8940-8944	from	_
50-4	8945-8949	this	_
50-5	8950-8958	modified	_
50-6	8959-8962	MID	_
50-7	8963-8967	task	_
50-8	8968-8976	included	_
50-9	8977-8980	the	_
50-10	8981-8991	proportion	_
50-11	8992-8994	of	_
50-12	8995-8999	hits	_
50-13	9000-9002	on	_
50-14	9003-9007	gain	_
50-15	9008-9014	trials	_
50-16	9015-9018	and	_
50-17	9019-9022	hit	_
50-18	9023-9031	reaction	_
50-19	9032-9037	times	_
50-20	9038-9039	.	_

51-1	9040-9042	At	_
51-2	9043-9046	all	_
51-3	9047-9052	sites	_
51-4	9053-9054	,	_
51-5	9055-9063	scanning	_
51-6	9064-9067	was	_
51-7	9068-9077	performed	_
51-8	9078-9082	with	_
51-9	9083-9084	3	_
51-10	9085-9086	T	_
51-11	9087-9097	whole-body	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-12	9098-9106	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-13	9107-9116	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-14	9117-9125	scanners	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-15	9126-9134	produced	_
51-16	9135-9137	by	_
51-17	9138-9139	a	_
51-18	9140-9147	variety	_
51-19	9148-9150	of	_
51-20	9151-9164	manufacturers	_
51-21	9165-9166	(	_
51-22	9167-9174	Siemens	_
51-23	9175-9176	,	_
51-24	9177-9184	Philips	_
51-25	9185-9186	,	_
51-26	9187-9194	General	_
51-27	9195-9203	Electric	_
51-28	9204-9207	and	_
51-29	9208-9214	Bruker	_
51-30	9215-9216	)	_
51-31	9217-9218	.	_

52-1	9219-9222	For	_
52-2	9223-9233	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-3	9234-9241	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-4	9242-9243	,	_
52-5	9244-9246	we	_
52-6	9247-9255	acquired	_
52-7	9256-9259	300	_
52-8	9260-9267	volumes	_
52-9	9268-9272	with	_
52-10	9273-9275	40	_
52-11	9276-9282	slices	_
52-12	9283-9285	in	_
52-13	9286-9296	descending	_
52-14	9297-9302	order	_
52-15	9303-9304	(	_
52-16	9305-9308	2.4	_
52-17	9309-9311	mm	_
52-18	9312-9317	slice	_
52-19	9318-9327	thickness	_
52-20	9328-9332	with	_
52-21	9333-9334	1	_
52-22	9335-9337	mm	_
52-23	9338-9341	gap	_
52-24	9342-9343	)	_
52-25	9344-9349	using	_
52-26	9350-9351	a	_
52-27	9352-9365	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-28	9366-9368	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-29	9369-9370	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-30	9371-9380	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-31	9381-9386	pulse	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-32	9387-9395	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-33	9396-9397	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-34	9398-9401	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-35	9402-9403	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
52-36	9404-9405	.	_

53-1	9406-9409	The	_
53-2	9410-9414	time	_
53-3	9415-9417	to	_
53-4	9418-9428	repetition	_
53-5	9429-9432	for	_
53-6	9433-9439	volume	_
53-7	9440-9451	acquisition	_
53-8	9452-9455	was	_
53-9	9456-9459	set	_
53-10	9460-9462	to	_
53-11	9463-9468	2,200	_
53-12	9469-9471	ms	_
53-13	9472-9475	and	_
53-14	9476-9479	the	_
53-15	9480-9484	time	_
53-16	9485-9487	to	_
53-17	9488-9492	echo	_
53-18	9493-9495	to	_
53-19	9496-9498	30	_
53-20	9499-9502	ms.	_
53-21	9503-9511	In-plane	_
53-22	9512-9522	resolution	_
53-23	9523-9526	was	_
53-24	9527-9529	64	_
53-25	9530-9531	×	_
53-26	9532-9534	64	_
53-27	9535-9539	with	_
53-28	9540-9541	a	_
53-29	9542-9547	field	_
53-30	9548-9550	of	_
53-31	9551-9555	view	_
53-32	9556-9558	of	_
53-33	9559-9562	220	_
53-34	9563-9564	×	_
53-35	9565-9568	220	_
53-36	9569-9571	mm	_
53-37	9572-9573	.	_

54-1	9574-9577	The	_
54-2	9578-9583	plane	_
54-3	9584-9586	of	_
54-4	9587-9598	acquisition	_
54-5	9599-9602	was	_
54-6	9603-9609	tilted	_
54-7	9610-9612	to	_
54-8	9613-9621	parallel	_
54-9	9622-9625	the	_
54-10	9626-9644	anterior–posterior	_
54-11	9645-9655	commissure	_
54-12	9656-9660	line	_
54-13	9661-9662	.	_

55-1	9663-9666	For	_
55-2	9667-9677	anatomical	_
55-3	9678-9687	reference	_
55-4	9688-9689	,	_
55-5	9690-9691	a	_
55-6	9692-9709	three-dimensional	_
55-7	9710-9723	magnetization	_
55-8	9724-9732	prepared	_
55-9	9733-9746	gradient-echo	_
55-10	9747-9755	sequence	_
55-11	9756-9758	of	_
55-12	9759-9762	the	_
55-13	9763-9768	whole	_
55-14	9769-9774	brain	_
55-15	9775-9778	was	_
55-16	9779-9787	obtained	_
55-17	9788-9792	with	_
55-18	9793-9797	time	_
55-19	9798-9800	to	_
55-20	9801-9811	repetition	_
55-21	9812-9814	of	_
55-22	9815-9818	6.8	_
55-23	9819-9821	ms	_
55-24	9822-9825	and	_
55-25	9826-9827	a	_
55-26	9828-9832	time	_
55-27	9833-9835	to	_
55-28	9836-9840	echo	_
55-29	9841-9843	of	_
55-30	9844-9847	3.2	_
55-31	9848-9850	ms	_
55-32	9851-9852	.	_

56-1	9853-9858	These	_
56-2	9859-9866	imaging	_
56-3	9867-9877	parameters	_
56-4	9878-9882	were	_
56-5	9883-9889	chosen	_
56-6	9890-9892	to	_
56-7	9893-9899	ensure	_
56-8	9900-9913	comparability	_
56-9	9914-9916	of	_
56-10	9917-9921	data	_
56-11	9922-9928	across	_
56-12	9929-9938	different	_
56-13	9939-9947	scanners	_
56-14	9948-9949	.	_

57-1	9950-9957	Further	_
57-2	9958-9965	details	_
57-3	9966-9968	of	_
57-4	9969-9972	the	_
57-5	9973-9978	image	_
57-6	9979-9990	acquisition	_
57-7	9991-10000	protocols	_
57-8	10001-10004	and	_
57-9	10005-10012	quality	_
57-10	10013-10020	control	_
57-11	10021-10031	procedures	_
57-12	10032-10036	have	_
57-13	10037-10041	been	_
57-14	10042-10051	described	_
57-15	10052-10062	previously	_
57-16	10063-10064	,	_
57-17	10065-10074	including	_
57-18	10075-10077	an	_
57-19	10078-10087	extensive	_
57-20	10088-10094	period	_
57-21	10095-10097	of	_
57-22	10098-10113	standardization	_
57-23	10114-10120	across	_
57-24	10121-10129	magnetic	_
57-25	10130-10139	resonance	_
57-26	10140-10148	scanners	_
57-27	10149-10150	.	_

58-1	10151-10156	Image	_
58-2	10157-10170	preprocessing	_
58-3	10171-10174	and	_
58-4	10175-10183	analyses	_
58-5	10184-10188	were	_
58-6	10189-10198	performed	_
58-7	10199-10203	with	_
58-8	10204-10208	SPM8	_
58-9	10209-10212	and	_
58-10	10213-10218	SPM12	_
58-11	10219-10227	software	_
58-12	10228-10229	(	_
58-13	10230-10238	Wellcome	_
58-14	10239-10244	Trust	_
58-15	10245-10251	Centre	_
58-16	10252-10255	for	_
58-17	10256-10268	Neuroimaging	_
58-18	10269-10270	,	_
58-19	10271-10277	London	_
58-20	10278-10279	)	_
58-21	10280-10281	.	_

59-1	10282-10285	For	_
59-2	10286-10296	structural	_
59-3	10297-10310	preprocessing	_
59-4	10311-10312	,	_
59-5	10313-10315	we	_
59-6	10316-10326	normalized	_
59-7	10327-10339	individually	_
59-8	10340-10349	segmented	_
59-9	10350-10361	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
59-10	10362-10367	scans	_
59-11	10368-10370	to	_
59-12	10371-10372	a	_
59-13	10373-10381	template	_
59-14	10382-10391	generated	_
59-15	10392-10394	by	_
59-16	10395-10398	the	_
59-17	10399-10404	first	_
59-18	10405-10408	552	_
59-19	10409-10420	adolescents	_
59-20	10421-10423	in	_
59-21	10424-10427	the	_
59-22	10428-10434	sample	_
59-23	10435-10440	using	_
59-24	10441-10444	the	_
59-25	10445-10451	DARTEL	_
59-26	10452-10459	toolbox	_
59-27	10460-10462	as	_
59-28	10463-10474	implemented	_
59-29	10475-10477	in	_
59-30	10478-10482	SPM8	_
59-31	10483-10484	.	_

60-1	10485-10488	For	_
60-2	10489-10493	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-3	10494-10505	whole-brain	_
60-4	10506-10514	analyses	_
60-5	10515-10516	,	_
60-6	10517-10531	single-subject	_
60-7	10532-10543	echo-planar	_
60-8	10544-10550	images	_
60-9	10551-10555	were	_
60-10	10556-10568	coregistered	_
60-11	10569-10573	with	_
60-12	10574-10579	their	_
60-13	10580-10590	associated	_
60-14	10591-10602	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
60-15	10603-10613	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
60-16	10614-10620	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
60-17	10621-10622	.	_

61-1	10623-10633	Functional	_
61-2	10634-10640	images	_
61-3	10641-10645	were	_
61-4	10646-10650	then	_
61-5	10651-10660	realigned	_
61-6	10661-10664	and	_
61-7	10665-10673	resliced	_
61-8	10674-10676	to	_
61-9	10677-10680	the	_
61-10	10681-10686	first	_
61-11	10687-10693	volume	_
61-12	10694-10695	.	_

62-1	10696-10710	Single-subject	_
62-2	10711-10722	statistical	_
62-3	10723-10729	models	_
62-4	10730-10738	analysed	_
62-5	10739-10742	the	_
62-6	10743-10751	resliced	_
62-7	10752-10756	data	_
62-8	10757-10762	using	_
62-9	10763-10766	the	_
62-10	10767-10776	following	_
62-11	10777-10787	regressors	_
62-12	10788-10789	:	_
62-13	10790-10791	(	_
62-14	10792-10793	1	_
62-15	10794-10795	)	_
62-16	10796-10808	anticipation	_
62-17	10809-10811	of	_
62-18	10812-10817	large	_
62-19	10818-10822	gain	_
62-20	10823-10824	;	_
62-21	10825-10826	(	_
62-22	10827-10828	2	_
62-23	10829-10830	)	_
62-24	10831-10843	anticipation	_
62-25	10844-10846	of	_
62-26	10847-10852	small	_
62-27	10853-10857	gain	_
62-28	10858-10859	;	_
62-29	10860-10861	(	_
62-30	10862-10863	3	_
62-31	10864-10865	)	_
62-32	10866-10878	anticipation	_
62-33	10879-10881	of	_
62-34	10882-10884	no	_
62-35	10885-10889	gain	_
62-36	10890-10891	;	_
62-37	10892-10893	(	_
62-38	10894-10895	4	_
62-39	10896-10897	)	_
62-40	10898-10906	feedback	_
62-41	10907-10917	indicating	_
62-42	10918-10923	large	_
62-43	10924-10928	gain	_
62-44	10929-10930	;	_
62-45	10931-10932	(	_
62-46	10933-10934	5	_
62-47	10935-10936	)	_
62-48	10937-10945	feedback	_
62-49	10946-10956	indicating	_
62-50	10957-10962	small	_
62-51	10963-10967	gain	_
62-52	10968-10969	;	_
62-53	10970-10971	(	_
62-54	10972-10973	6	_
62-55	10974-10975	)	_
62-56	10976-10979	and	_
62-57	10980-10988	feedback	_
62-58	10989-10999	indicating	_
62-59	11000-11002	no	_
62-60	11003-11007	gain	_
62-61	11008-11009	.	_

63-1	11010-11014	Each	_
63-2	11015-11024	regressor	_
63-3	11025-11028	was	_
63-4	11029-11036	defined	_
63-5	11037-11047	separately	_
63-6	11048-11051	for	_
63-7	11052-11062	successful	_
63-8	11063-11064	(	_
63-9	11065-11069	that	_
63-10	11070-11072	is	_
63-11	11073-11074	,	_
63-12	11075-11076	‘	_
63-13	11077-11081	hits	_
63-14	11082-11083	'	_
63-15	11084-11085	)	_
63-16	11086-11088	as	_
63-17	11089-11093	well	_
63-18	11094-11096	as	_
63-19	11097-11109	unsuccessful	_
63-20	11110-11111	(	_
63-21	11112-11116	that	_
63-22	11117-11119	is	_
63-23	11120-11121	,	_
63-24	11122-11123	‘	_
63-25	11124-11130	misses	_
63-26	11131-11132	'	_
63-27	11133-11134	)	_
63-28	11135-11143	response	_
63-29	11144-11150	trials	_
63-30	11151-11152	.	_

64-1	11153-11157	Thus	_
64-2	11158-11159	,	_
64-3	11160-11164	each	_
64-4	11165-11170	model	_
64-5	11171-11179	included	_
64-6	11180-11181	a	_
64-7	11182-11187	total	_
64-8	11188-11190	of	_
64-9	11191-11193	12	_
64-10	11194-11204	orthogonal	_
64-11	11205-11215	regressors	_
64-12	11216-11217	.	_

65-1	11218-11224	Trials	_
65-2	11225-11227	in	_
65-3	11228-11233	which	_
65-4	11234-11242	subjects	_
65-5	11243-11249	failed	_
65-6	11250-11252	to	_
65-7	11253-11260	respond	_
65-8	11261-11265	were	_
65-9	11266-11274	modelled	_
65-10	11275-11284	similarly	_
65-11	11285-11288	but	_
65-12	11289-11299	separately	_
65-13	11300-11302	as	_
65-14	11303-11308	error	_
65-15	11309-11315	trials	_
65-16	11316-11317	.	_

66-1	11318-11323	Rigid	_
66-2	11324-11328	body	_
66-3	11329-11337	movement	_
66-4	11338-11348	parameters	_
66-5	11349-11353	from	_
66-6	11354-11357	the	_
66-7	11358-11369	realignment	_
66-8	11370-11379	procedure	_
66-9	11380-11384	were	_
66-10	11385-11393	included	_
66-11	11394-11396	as	_
66-12	11397-11400	six	_
66-13	11401-11411	additional	_
66-14	11412-11422	covariates	_
66-15	11423-11424	.	_

67-1	11425-11429	Next	_
67-2	11430-11431	,	_
67-3	11432-11440	contrast	_
67-4	11441-11447	images	_
67-5	11448-11450	of	_
67-6	11451-11454	the	_
67-7	11455-11464	parameter	_
67-8	11465-11474	estimates	_
67-9	11475-11479	were	_
67-10	11480-11487	created	_
67-11	11488-11491	for	_
67-12	11492-11496	each	_
67-13	11497-11504	subject	_
67-14	11505-11506	.	_

68-1	11507-11510	The	_
68-2	11511-11518	present	_
68-3	11519-11527	analyses	_
68-4	11528-11535	focused	_
68-5	11536-11538	on	_
68-6	11539-11542	the	_
68-7	11543-11547	gain	_
68-8	11548-11560	anticipation	_
68-9	11561-11566	phase	_
68-10	11567-11568	.	_

69-1	11569-11577	Analyses	_
69-2	11578-11590	specifically	_
69-3	11591-11601	contrasted	_
69-4	11602-11608	neural	_
69-5	11609-11618	responses	_
69-6	11619-11625	during	_
69-7	11626-11638	anticipation	_
69-8	11639-11641	of	_
69-9	11642-11647	large	_
69-10	11648-11654	versus	_
69-11	11655-11660	small	_
69-12	11661-11665	gain	_
69-13	11666-11667	,	_
69-14	11668-11673	since	_
69-15	11674-11679	motor	_
69-16	11680-11689	responses	_
69-17	11690-11693	did	_
69-18	11694-11697	not	_
69-19	11698-11704	differ	_
69-20	11705-11711	across	_
69-21	11712-11724	incentivized	_
69-22	11725-11735	conditions	_
69-23	11736-11743	between	_
69-24	11744-11750	groups	_
69-25	11751-11752	(	_
69-26	11753-11756	but	_
69-27	11757-11761	were	_
69-28	11762-11770	slightly	_
69-29	11771-11776	lower	_
69-30	11777-11779	in	_
69-31	11780-11790	vulnerable	_
69-32	11791-11799	subjects	_
69-33	11800-11803	for	_
69-34	11804-11806	no	_
69-35	11807-11811	gain	_
69-36	11812-11818	trials	_
69-37	11819-11820	;	_
69-38	11821-11826	Table	_
69-39	11827-11828	1	_
69-40	11829-11830	)	_
69-41	11831-11832	.	_

70-1	11833-11847	Single-subject	_
70-2	11848-11856	contrast	_
70-3	11857-11863	images	_
70-4	11864-11868	were	_
70-5	11869-11876	created	_
70-6	11877-11879	by	_
70-7	11880-11888	applying	_
70-8	11889-11892	the	_
70-9	11893-11899	DARTEL	_
70-10	11900-11912	deformations	_
70-11	11913-11915	to	_
70-12	11916-11919	the	_
70-13	11920-11928	contrast	_
70-14	11929-11935	images	_
70-15	11936-11937	,	_
70-16	11938-11943	which	_
70-17	11944-11948	were	_
70-18	11949-11961	subsequently	_
70-19	11962-11970	smoothed	_
70-20	11971-11975	with	_
70-21	11976-11977	a	_
70-22	11978-11986	Gaussian	_
70-23	11987-11993	kernel	_
70-24	11994-11996	of	_
70-25	11997-11998	8	_
70-26	11999-12001	mm	_
70-27	12002-12006	full	_
70-28	12007-12012	width	_
70-29	12013-12015	at	_
70-30	12016-12020	half	_
70-31	12021-12028	maximum	_
70-32	12029-12030	.	_

71-1	12031-12041	Normalized	_
71-2	12042-12045	and	_
71-3	12046-12054	smoothed	_
71-4	12055-12069	single-subject	_
71-5	12070-12078	contrast	_
71-6	12079-12085	images	_
71-7	12086-12090	were	_
71-8	12091-12095	then	_
71-9	12096-12103	entered	_
71-10	12104-12108	into	_
71-11	12109-12110	a	_
71-12	12111-12123	second-level	_
71-13	12124-12138	random-effects	_
71-14	12139-12147	analysis	_
71-15	12148-12149	(	_
71-16	12150-12160	two-sample	_
71-17	12161-12167	t-test	_
71-18	12168-12179	contrasting	_
71-19	12180-12183	PDU	_
71-20	12184-12192	subjects	_
71-21	12193-12199	versus	_
71-22	12200-12208	controls	_
71-23	12209-12210	)	_
71-24	12211-12212	.	_

72-1	12213-12221	Although	_
72-2	12222-12226	both	_
72-3	12227-12233	groups	_
72-4	12234-12238	were	_
72-5	12239-12246	matched	_
72-6	12247-12250	for	_
72-7	12251-12257	gender	_
72-8	12258-12259	,	_
72-9	12260-12268	pubertal	_
72-10	12269-12275	status	_
72-11	12276-12277	,	_
72-12	12278-12290	intelligence	_
72-13	12291-12299	estimate	_
72-14	12300-12301	,	_
72-15	12302-12307	ESPAD	_
72-16	12308-12317	composite	_
72-17	12318-12323	score	_
72-18	12324-12325	,	_
72-19	12326-12341	novelty-seeking	_
72-20	12342-12347	score	_
72-21	12348-12351	and	_
72-22	12352-12360	scanning	_
72-23	12361-12365	site	_
72-24	12366-12368	at	_
72-25	12369-12372	the	_
72-26	12373-12378	first	_
72-27	12379-12389	assessment	_
72-28	12390-12391	,	_
72-29	12392-12394	we	_
72-30	12395-12403	included	_
72-31	12404-12409	those	_
72-32	12410-12419	variables	_
72-33	12420-12422	as	_
72-34	12423-12433	covariates	_
72-35	12434-12436	to	_
72-36	12437-12444	account	_
72-37	12445-12448	for	_
72-38	12449-12457	residual	_
72-39	12458-12466	variance	_
72-40	12467-12474	between	_
72-41	12475-12478	and	_
72-42	12479-12485	within	_
72-43	12486-12492	groups	_
72-44	12493-12494	.	_

73-1	12495-12498	For	_
73-2	12499-12510	whole-brain	_
73-3	12511-12519	analyses	_
73-4	12520-12521	,	_
73-5	12522-12527	which	_
73-6	12528-12532	were	_
73-7	12533-12542	primarily	_
73-8	12543-12551	intended	_
73-9	12552-12554	to	_
73-10	12555-12561	verify	_
73-11	12562-12566	main	_
73-12	12567-12574	effects	_
73-13	12575-12577	of	_
73-14	12578-12581	the	_
73-15	12582-12594	neuroimaging	_
73-16	12595-12599	task	_
73-17	12600-12606	across	_
73-18	12607-12613	groups	_
73-19	12614-12617	and	_
73-20	12618-12623	group	_
73-21	12624-12635	differences	_
73-22	12636-12638	in	_
73-23	12639-12648	predicted	_
73-24	12649-12656	regions	_
73-25	12657-12658	,	_
73-26	12659-12662	the	_
73-27	12663-12672	threshold	_
73-28	12673-12676	was	_
73-29	12677-12680	set	_
73-30	12681-12683	to	_
73-31	12684-12685	P	_
73-32	12686-12687	<	_
73-33	12688-12692	0.05	_
73-34	12693-12694	,	_
73-35	12695-12704	corrected	_
73-36	12705-12708	for	_
73-37	12709-12717	multiple	_
73-38	12718-12729	comparisons	_
73-39	12730-12731	.	_

74-1	12732-12735	For	_
74-2	12736-12744	targeted	_
74-3	12745-12753	analyses	_
74-4	12754-12758	that	_
74-5	12759-12765	tested	_
74-6	12766-12769	the	_
74-7	12770-12778	critical	_
74-8	12779-12789	hypotheses	_
74-9	12790-12791	,	_
74-10	12792-12801	bilateral	_
74-11	12802-12809	ventral	_
74-12	12810-12818	striatal	_
74-13	12819-12828	spherical	_
74-14	12829-12830	(	_
74-15	12831-12833	12	_
74-16	12834-12836	mm	_
74-17	12837-12845	diameter	_
74-18	12846-12847	)	_
74-19	12848-12855	volumes	_
74-20	12856-12858	of	_
74-21	12859-12867	interest	_
74-22	12868-12869	(	_
74-23	12870-12874	VOIs	_
74-24	12875-12876	)	_
74-25	12877-12881	were	_
74-26	12882-12889	centred	_
74-27	12890-12892	on	_
74-28	12893-12901	Montreal	_
74-29	12902-12914	Neurological	_
74-30	12915-12924	Institute	_
74-31	12925-12936	coordinates	_
74-32	12937-12940	±14	_
74-33	12941-12942	,	_
74-34	12943-12944	8	_
74-35	12945-12946	,	_
74-36	12947-12949	–8	_
74-37	12950-12951	(	_
74-38	12952-12955	ref	_
74-39	12956-12957	.	_

75-1	12958-12959	)	_
75-2	12960-12961	,	_
75-3	12962-12964	as	_
75-4	12965-12975	documented	_
75-5	12976-12978	in	_
75-6	12979-12987	previous	_
75-7	12988-12996	research	_
75-8	12997-12999	on	_
75-9	13000-13006	reward	_
75-10	13007-13019	anticipation	_
75-11	13020-13021	.	_

76-1	13022-13031	Similarly	_
76-2	13032-13033	,	_
76-3	13034-13043	bilateral	_
76-4	13044-13052	midbrain	_
76-5	13053-13062	spherical	_
76-6	13063-13064	(	_
76-7	13065-13067	12	_
76-8	13068-13070	mm	_
76-9	13071-13079	diameter	_
76-10	13080-13081	)	_
76-11	13082-13086	VOIs	_
76-12	13087-13091	were	_
76-13	13092-13099	centred	_
76-14	13100-13102	on	_
76-15	13103-13114	coordinates	_
76-16	13115-13117	±9	_
76-17	13118-13119	,	_
76-18	13120-13123	–15	_
76-19	13124-13125	,	_
76-20	13126-13129	–15	_
76-21	13130-13131	(	_
76-22	13132-13135	ref	_
76-23	13136-13137	.	_

77-1	13138-13139	)	_
77-2	13140-13141	,	_
77-3	13142-13144	as	_
77-4	13145-13155	documented	_
77-5	13156-13158	in	_
77-6	13159-13167	previous	_
77-7	13168-13176	research	_
77-8	13177-13179	on	_
77-9	13180-13186	reward	_
77-10	13187-13199	anticipation	_
77-11	13200-13201	.	_

78-1	13202-13211	Bilateral	_
78-2	13212-13224	dorsolateral	_
78-3	13225-13228	PFC	_
78-4	13229-13238	spherical	_
78-5	13239-13240	(	_
78-6	13241-13243	40	_
78-7	13244-13246	mm	_
78-8	13247-13255	diameter	_
78-9	13256-13257	)	_
78-10	13258-13262	VOIs	_
78-11	13263-13267	were	_
78-12	13268-13275	centred	_
78-13	13276-13278	on	_
78-14	13279-13290	coordinates	_
78-15	13291-13294	±35	_
78-16	13295-13296	,	_
78-17	13297-13299	36	_
78-18	13300-13301	,	_
78-19	13302-13304	32	_
78-20	13305-13306	(	_
78-21	13307-13310	ref	_
78-22	13311-13312	.	_

79-1	13313-13314	)	_
79-2	13315-13316	,	_
79-3	13317-13322	based	_
79-4	13323-13325	on	_
79-5	13326-13334	previous	_
79-6	13335-13343	research	_
79-7	13344-13346	on	_
79-8	13347-13356	executive	_
79-9	13357-13364	control	_
79-10	13365-13366	.	_

80-1	13367-13372	Tests	_
80-2	13373-13376	for	_
80-3	13377-13389	associations	_
80-4	13390-13392	of	_
80-5	13393-13401	activity	_
80-6	13402-13404	in	_
80-7	13405-13410	these	_
80-8	13411-13415	VOIs	_
80-9	13416-13418	at	_
80-10	13419-13422	age	_
80-11	13423-13425	14	_
80-12	13426-13430	with	_
80-13	13431-13439	eventual	_
80-14	13440-13443	PDU	_
80-15	13444-13450	versus	_
80-16	13451-13458	healthy	_
80-17	13459-13465	status	_
80-18	13466-13468	at	_
80-19	13469-13472	age	_
80-20	13473-13475	16	_
80-21	13476-13480	were	_
80-22	13481-13501	Bonferroni-corrected	_
80-23	13502-13505	for	_
80-24	13506-13514	multiple	_
80-25	13515-13526	comparisons	_
80-26	13527-13528	(	_
80-27	13529-13530	P	_
80-28	13531-13532	<	_
80-29	13533-13541	0.05/6=P	_
80-30	13542-13543	<	_
80-31	13544-13549	0.008	_
80-32	13550-13551	)	_
80-33	13552-13553	.	_

81-1	13554-13556	In	_
81-2	13557-13564	figures	_
81-3	13565-13566	,	_
81-4	13567-13574	results	_
81-5	13575-13578	are	_
81-6	13579-13588	displayed	_
81-7	13589-13591	at	_
81-8	13592-13593	a	_
81-9	13594-13603	threshold	_
81-10	13604-13606	of	_
81-11	13607-13608	P	_
81-12	13609-13610	<	_
81-13	13611-13616	0.005	_
81-14	13617-13628	uncorrected	_
81-15	13629-13633	with	_
81-16	13634-13642	clusters	_
81-17	13643-13652	including	_
81-18	13653-13655	at	_
81-19	13656-13661	least	_
81-20	13662-13664	10	_
81-21	13665-13675	contiguous	_
81-22	13676-13682	voxels	_
81-23	13683-13686	and	_
81-24	13687-13696	projected	_
81-25	13697-13701	onto	_
81-26	13702-13705	the	_
81-27	13706-13710	mean	_
81-28	13711-13721	structural	_
81-29	13722-13726	scan	_
81-30	13727-13729	of	_
81-31	13730-13733	all	_
81-32	13734-13742	subjects	_
81-33	13743-13744	,	_
81-34	13745-13748	but	_
81-35	13749-13754	these	_
81-36	13755-13759	VOIs	_
81-37	13760-13763	are	_
81-38	13764-13776	superimposed	_
81-39	13777-13780	for	_
81-40	13781-13794	visualization	_
81-41	13795-13803	purposes	_
81-42	13804-13805	(	_
81-43	13806-13810	Figs	_
81-44	13811-13812	2	_
81-45	13813-13814	,	_
81-46	13815-13816	3	_
81-47	13817-13818	,	_
81-48	13819-13820	4	_
81-49	13821-13822	)	_
81-50	13823-13824	.	_

82-1	13825-13830	Since	_
82-2	13831-13834	the	_
82-3	13835-13842	average	_
82-4	13843-13853	adolescent	_
82-5	13854-13859	brain	_
82-6	13860-13862	at	_
82-7	13863-13866	age	_
82-8	13867-13869	14	_
82-9	13870-13872	is	_
82-10	13873-13880	smaller	_
82-11	13881-13885	than	_
82-12	13886-13889	the	_
82-13	13890-13895	adult	_
82-14	13896-13901	brain	_
82-15	13902-13903	,	_
82-16	13904-13906	we	_
82-17	13907-13916	refrained	_
82-18	13917-13921	from	_
82-19	13922-13934	transforming	_
82-20	13935-13945	individual	_
82-21	13946-13952	brains	_
82-22	13953-13957	into	_
82-23	13958-13963	adult	_
82-24	13964-13967	MNI	_
82-25	13968-13973	space	_
82-26	13974-13975	.	_

83-1	13976-13983	However	_
83-2	13984-13985	,	_
83-3	13986-13991	since	_
83-4	13992-13995	the	_
83-5	13996-14007	predictions	_
83-6	14008-14012	came	_
83-7	14013-14017	from	_
83-8	14018-14025	studies	_
83-9	14026-14030	that	_
83-10	14031-14039	reported	_
83-11	14040-14044	data	_
83-12	14045-14047	in	_
83-13	14048-14051	MNI	_
83-14	14052-14057	space	_
83-15	14058-14059	,	_
83-16	14060-14062	we	_
83-17	14063-14072	estimated	_
83-18	14073-14076	the	_
83-19	14077-14087	parameters	_
83-20	14088-14091	for	_
83-21	14092-14098	linear	_
83-22	14099-14113	transformation	_
83-23	14114-14118	from	_
83-24	14119-14122	MNI	_
83-25	14123-14128	space	_
83-26	14129-14131	to	_
83-27	14132-14135	the	_
83-28	14136-14141	space	_
83-29	14142-14144	of	_
83-30	14145-14148	our	_
83-31	14149-14155	DARTEL	_
83-32	14156-14164	template	_
83-33	14165-14166	(	_
83-34	14167-14171	that	_
83-35	14172-14174	is	_
83-36	14175-14176	,	_
83-37	14177-14184	X=0.892	_
83-38	14185-14186	,	_
83-39	14187-14199	·XMNI=−0.008	_
83-40	14200-14201	,	_
83-41	14202-14214	·YMNI=+0.004	_
83-42	14215-14216	,	_
83-43	14217-14229	·ZMNI=+0.385	_
83-44	14230-14231	;	_
83-45	14232-14239	Y=0.017	_
83-46	14240-14241	,	_
83-47	14242-14254	·XMNI=+0.930	_
83-48	14255-14256	,	_
83-49	14257-14269	·YMNI=+0.025	_
83-50	14270-14271	,	_
83-51	14272-14284	·ZMNI=−6.799	_
83-52	14285-14286	;	_
83-53	14287-14294	Z=0.009	_
83-54	14295-14296	,	_
83-55	14297-14309	·XMNI=−0.005	_
83-56	14310-14311	,	_
83-57	14312-14324	·YMNI=+0.838	_
83-58	14325-14326	,	_
83-59	14327-14339	·ZMNI=−0.093	_
83-60	14340-14341	)	_
83-61	14342-14343	.	_

84-1	14344-14354	Structural	_
84-2	14355-14367	neuroimaging	_
84-3	14368-14372	data	_
84-4	14373-14381	analysis	_
84-5	14382-14393	Voxel-based	_
84-6	14394-14405	morphometry	_
84-7	14406-14414	analyses	_
84-8	14415-14423	compared	_
84-9	14424-14433	spatially	_
84-10	14434-14444	normalized	_
84-11	14445-14455	structural	_
84-12	14456-14461	scans	_
84-13	14462-14464	on	_
84-14	14465-14466	a	_
84-15	14467-14481	voxel-by-voxel	_
84-16	14482-14487	basis	_
84-17	14488-14489	.	_

85-1	14490-14497	Instead	_
85-2	14498-14500	of	_
85-3	14501-14509	directly	_
85-4	14510-14519	comparing	_
85-5	14520-14525	image	_
85-6	14526-14535	intensity	_
85-7	14536-14537	,	_
85-8	14538-14545	however	_
85-9	14546-14547	,	_
85-10	14548-14558	structural	_
85-11	14559-14564	scans	_
85-12	14565-14569	were	_
85-13	14570-14579	segmented	_
85-14	14580-14584	into	_
85-15	14585-14589	grey	_
85-16	14590-14593	and	_
85-17	14594-14599	white	_
85-18	14600-14606	matter	_
85-19	14607-14608	,	_
85-20	14609-14617	smoothed	_
85-21	14618-14619	,	_
85-22	14620-14623	and	_
85-23	14624-14628	then	_
85-24	14629-14632	the	_
85-25	14633-14637	grey	_
85-26	14638-14644	matter	_
85-27	14645-14654	partition	_
85-28	14655-14658	was	_
85-29	14659-14668	subjected	_
85-30	14669-14671	to	_
85-31	14672-14673	a	_
85-32	14674-14688	voxel-by-voxel	_
85-33	14689-14700	statistical	_
85-34	14701-14705	test	_
85-35	14706-14707	.	_

86-1	14708-14712	Thus	_
86-2	14713-14714	,	_
86-3	14715-14717	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
86-4	14718-14724	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
86-5	14725-14729	were	_
86-6	14730-14739	segmented	_
86-7	14740-14745	using	_
86-8	14746-14749	the	_
86-9	14750-14751	‘	_
86-10	14752-14755	new	_
86-11	14756-14763	segment	_
86-12	14764-14765	'	_
86-13	14766-14773	routine	_
86-14	14774-14776	as	_
86-15	14777-14788	implemented	_
86-16	14789-14791	in	_
86-17	14792-14796	SPM8	_
86-18	14797-14798	,	_
86-19	14799-14803	then	_
86-20	14804-14813	modulated	_
86-21	14814-14817	and	_
86-22	14818-14827	spatially	_
86-23	14828-14838	normalized	_
86-24	14839-14843	with	_
86-25	14844-14850	DARTEL	_
86-26	14851-14852	(	_
86-27	14853-14856	see	_
86-28	14857-14862	above	_
86-29	14863-14864	)	_
86-30	14865-14866	.	_

87-1	14867-14876	Resulting	_
87-2	14877-14883	images	_
87-3	14884-14888	were	_
87-4	14889-14897	smoothed	_
87-5	14898-14902	with	_
87-6	14903-14904	a	_
87-7	14905-14913	Gaussian	_
87-8	14914-14920	kernel	_
87-9	14921-14923	of	_
87-10	14924-14925	8	_
87-11	14926-14928	mm	_
87-12	14929-14933	full	_
87-13	14934-14939	width	_
87-14	14940-14942	at	_
87-15	14943-14947	half	_
87-16	14948-14955	maximum	_
87-17	14956-14957	.	_

88-1	14958-14969	Statistical	_
88-2	14970-14978	analyses	_
88-3	14979-14987	mirrored	_
88-4	14988-14993	those	_
88-5	14994-15001	applied	_
88-6	15002-15004	to	_
88-7	15005-15008	the	_
88-8	15009-15013	fMRI	_
88-9	15014-15023	contrasts	_
88-10	15024-15025	(	_
88-11	15026-15030	that	_
88-12	15031-15033	is	_
88-13	15034-15035	,	_
88-14	15036-15046	two-sample	_
88-15	15047-15053	t-test	_
88-16	15054-15065	contrasting	_
88-17	15066-15069	PDU	_
88-18	15070-15078	subjects	_
88-19	15079-15085	versus	_
88-20	15086-15094	controls	_
88-21	15095-15096	,	_
88-22	15097-15101	with	_
88-23	15102-15108	gender	_
88-24	15109-15110	,	_
88-25	15111-15119	pubertal	_
88-26	15120-15126	status	_
88-27	15127-15128	,	_
88-28	15129-15141	intelligence	_
88-29	15142-15150	quotient	_
88-30	15151-15159	estimate	_
88-31	15160-15161	,	_
88-32	15162-15167	ESPAD	_
88-33	15168-15173	score	_
88-34	15174-15175	,	_
88-35	15176-15191	novelty-seeking	_
88-36	15192-15197	score	_
88-37	15198-15201	and	_
88-38	15202-15210	scanning	_
88-39	15211-15215	site	_
88-40	15216-15223	entered	_
88-41	15224-15226	as	_
88-42	15227-15237	covariates	_
88-43	15238-15240	of	_
88-44	15241-15243	no	_
88-45	15244-15252	interest	_
88-46	15253-15254	)	_
88-47	15255-15256	.	_

89-1	15257-15265	Targeted	_
89-2	15266-15274	analyses	_
89-3	15275-15283	compared	_
89-4	15284-15288	grey	_
89-5	15289-15295	matter	_
89-6	15296-15303	density	_
89-7	15304-15310	within	_
89-8	15311-15314	the	_
89-9	15315-15319	same	_
89-10	15320-15324	VOIs	_
89-11	15325-15329	that	_
89-12	15330-15334	were	_
89-13	15335-15346	constructed	_
89-14	15347-15349	to	_
89-15	15350-15357	compare	_
89-16	15358-15368	functional	_
89-17	15369-15377	activity	_
89-18	15378-15379	.	_

90-1	15380-15391	Behavioural	_
90-2	15392-15395	and	_
90-3	15396-15402	neural	_
90-4	15403-15413	prediction	_
90-5	15414-15416	of	_
90-6	15417-15420	PDU	_
90-7	15421-15426	After	_
90-8	15427-15436	verifying	_
90-9	15437-15440	key	_
90-10	15441-15453	psychometric	_
90-11	15454-15457	and	_
90-12	15458-15464	neural	_
90-13	15465-15474	variables	_
90-14	15475-15477	at	_
90-15	15478-15481	age	_
90-16	15482-15484	14	_
90-17	15485-15486	,	_
90-18	15487-15492	these	_
90-19	15493-15502	variables	_
90-20	15503-15504	'	_
90-21	15505-15513	relative	_
90-22	15514-15521	ability	_
90-23	15522-15524	to	_
90-24	15525-15532	predict	_
90-25	15533-15544	problematic	_
90-26	15545-15550	abuse	_
90-27	15551-15553	at	_
90-28	15554-15557	age	_
90-29	15558-15560	16	_
90-30	15561-15564	was	_
90-31	15565-15574	evaluated	_
90-32	15575-15580	using	_
90-33	15581-15582	a	_
90-34	15583-15589	series	_
90-35	15590-15592	of	_
90-36	15593-15601	logistic	_
90-37	15602-15612	regression	_
90-38	15613-15619	models	_
90-39	15620-15624	that	_
90-40	15625-15633	included	_
90-41	15634-15646	psychometric	_
90-42	15647-15656	variables	_
90-43	15657-15661	only	_
90-44	15662-15663	,	_
90-45	15664-15670	neural	_
90-46	15671-15680	variables	_
90-47	15681-15685	only	_
90-48	15686-15687	(	_
90-49	15688-15695	maximum	_
90-50	15696-15701	peaks	_
90-51	15702-15706	from	_
90-52	15707-15711	VOIs	_
90-53	15712-15713	)	_
90-54	15714-15715	,	_
90-55	15716-15719	and	_
90-56	15720-15723	the	_
90-57	15724-15735	combination	_
90-58	15736-15738	of	_
90-59	15739-15751	psychometric	_
90-60	15752-15755	and	_
90-61	15756-15762	neural	_
90-62	15763-15772	variables	_
90-63	15773-15774	.	_

91-1	15775-15780	Since	_
91-2	15781-15785	data	_
91-3	15786-15792	checks	_
91-4	15793-15795	of	_
91-5	15796-15805	pair-wise	_
91-6	15806-15818	correlations	_
91-7	15819-15827	revealed	_
91-8	15828-15832	that	_
91-9	15833-15841	activity	_
91-10	15842-15844	in	_
91-11	15845-15853	midbrain	_
91-12	15854-15857	and	_
91-13	15858-15867	bilateral	_
91-14	15868-15875	ventral	_
91-15	15876-15884	striatal	_
91-16	15885-15889	VOIs	_
91-17	15890-15893	was	_
91-18	15894-15900	highly	_
91-19	15901-15911	correlated	_
91-20	15912-15913	(	_
91-21	15914-15927	Supplementary	_
91-22	15928-15931	Fig	_
91-23	15932-15933	.	_

92-1	15934-15935	7	_
92-2	15936-15937	)	_
92-3	15938-15939	,	_
92-4	15940-15943	and	_
92-5	15944-15949	based	_
92-6	15950-15952	on	_
92-7	15953-15961	previous	_
92-8	15962-15970	evidence	_
92-9	15971-15979	reliably	_
92-10	15980-15991	implicating	_
92-11	15992-15999	ventral	_
92-12	16000-16008	striatal	_
92-13	16009-16017	activity	_
92-14	16018-16020	in	_
92-15	16021-16027	reward	_
92-16	16028-16040	anticipation	_
92-17	16041-16042	,	_
92-18	16043-16045	we	_
92-19	16046-16054	included	_
92-20	16055-16067	coefficients	_
92-21	16068-16071	for	_
92-22	16072-16075	the	_
92-23	16076-16081	right	_
92-24	16082-16089	ventral	_
92-25	16090-16098	striatal	_
92-26	16099-16102	VOI	_
92-27	16103-16105	in	_
92-28	16106-16109	the	_
92-29	16110-16116	models	_
92-30	16117-16118	.	_

93-1	16119-16128	Similarly	_
93-2	16129-16130	,	_
93-3	16131-16136	since	_
93-4	16137-16145	activity	_
93-5	16146-16148	in	_
93-6	16149-16152	the	_
93-7	16153-16156	two	_
93-8	16157-16169	dorsolateral	_
93-9	16170-16180	prefrontal	_
93-10	16181-16185	VOIs	_
93-11	16186-16189	was	_
93-12	16190-16196	highly	_
93-13	16197-16207	correlated	_
93-14	16208-16209	,	_
93-15	16210-16213	the	_
93-16	16214-16224	prefrontal	_
93-17	16225-16231	region	_
93-18	16232-16237	whose	_
93-19	16238-16246	activity	_
93-20	16247-16250	was	_
93-21	16251-16255	most	_
93-22	16256-16263	closely	_
93-23	16264-16274	associated	_
93-24	16275-16279	with	_
93-25	16280-16286	future	_
93-26	16287-16290	PDU	_
93-27	16291-16294	was	_
93-28	16295-16303	included	_
93-29	16304-16306	in	_
93-30	16307-16310	the	_
93-31	16311-16317	models	_
93-32	16318-16319	.	_

94-1	16320-16324	This	_
94-2	16325-16332	initial	_
94-3	16333-16341	variable	_
94-4	16342-16351	selection	_
94-5	16352-16359	averted	_
94-6	16360-16372	collinearity	_
94-7	16373-16376	and	_
94-8	16377-16386	resulting	_
94-9	16387-16398	instability	_
94-10	16399-16403	that	_
94-11	16404-16409	might	_
94-12	16410-16415	arise	_
94-13	16416-16420	from	_
94-14	16421-16430	including	_
94-15	16431-16437	highly	_
94-16	16438-16448	correlated	_
94-17	16449-16458	variables	_
94-18	16459-16461	in	_
94-19	16462-16465	the	_
94-20	16466-16470	same	_
94-21	16471-16476	model	_
94-22	16477-16478	.	_

95-1	16479-16495	Cross-validation	_
95-2	16496-16504	analyses	_
95-3	16505-16513	verified	_
95-4	16514-16518	that	_
95-5	16519-16524	these	_
95-6	16525-16534	variables	_
95-7	16535-16540	could	_
95-8	16541-16549	classify	_
95-9	16550-16556	future	_
95-10	16557-16560	PDU	_
95-11	16561-16564	out	_
95-12	16565-16567	of	_
95-13	16568-16574	sample	_
95-14	16575-16577	in	_
95-15	16578-16582	each	_
95-16	16583-16588	model	_
95-17	16589-16590	.	_

96-1	16591-16605	Classification	_
96-2	16606-16609	was	_
96-3	16610-16620	determined	_
96-4	16621-16626	using	_
96-5	16627-16634	10-fold	_
96-6	16635-16651	cross-validation	_
96-7	16652-16656	over	_
96-8	16657-16661	fits	_
96-9	16662-16664	of	_
96-10	16665-16666	a	_
96-11	16667-16673	linear	_
96-12	16674-16681	support	_
96-13	16682-16688	vector	_
96-14	16689-16696	machine	_
96-15	16697-16698	,	_
96-16	16699-16703	with	_
96-17	16704-16706	50	_
96-18	16707-16708	%	_
96-19	16709-16723	classification	_
96-20	16724-16736	representing	_
96-21	16737-16743	chance	_
96-22	16744-16745	.	_

97-1	16746-16750	Data	_
97-2	16751-16763	availability	_
97-3	16764-16768	Data	_
97-4	16769-16772	are	_
97-5	16773-16782	available	_
97-6	16783-16786	via	_
97-7	16787-16798	application	_
97-8	16799-16801	to	_
97-9	16802-16805	the	_
97-10	16806-16812	IMAGEN	_
97-11	16813-16820	project	_
97-12	16821-16822	(	_
97-13	16823-16827	http	_
97-14	16828-16829	:	_
97-15	16830-16853	//www.imagen-europe.com	_
97-16	16854-16855	)	_
97-17	16856-16857	.	_

98-1	16858-16868	Additional	_
98-2	16869-16880	information	_
98-3	16881-16884	How	_
98-4	16885-16887	to	_
98-5	16888-16892	cite	_
98-6	16893-16897	this	_
98-7	16898-16905	article	_
98-8	16906-16907	:	_
98-9	16908-16914	Büchel	_
98-10	16915-16916	,	_
98-11	16917-16919	C.	_
98-12	16920-16922	et	_
98-13	16923-16925	al	_
98-14	16926-16927	.	_

99-1	16928-16935	Blunted	_
99-2	16936-16943	ventral	_
99-3	16944-16952	striatal	_
99-4	16953-16962	responses	_
99-5	16963-16965	to	_
99-6	16966-16977	anticipated	_
99-7	16978-16985	rewards	_
99-8	16986-16996	foreshadow	_
99-9	16997-17008	problematic	_
99-10	17009-17013	drug	_
99-11	17014-17017	use	_
99-12	17018-17020	in	_
99-13	17021-17036	novelty-seeking	_
99-14	17037-17048	adolescents	_
99-15	17049-17050	.	_

100-1	17051-17054	Nat	_
100-2	17055-17056	.	_

101-1	17057-17063	Commun	_
101-2	17064-17065	.	_

102-1	17066-17067	8	_
102-2	17068-17069	,	_
102-3	17070-17075	14140	_
102-4	17076-17079	doi	_
102-5	17080-17081	:	_
102-6	17082-17101	10.1038/ncomms14140	_
102-7	17102-17103	(	_
102-8	17104-17108	2017	_
102-9	17109-17110	)	_
102-10	17111-17112	.	_

103-1	17113-17122	Publisher	_
103-2	17123-17125	's	_
103-3	17126-17130	note	_
103-4	17131-17132	:	_
103-5	17133-17141	Springer	_
103-6	17142-17148	Nature	_
103-7	17149-17156	remains	_
103-8	17157-17164	neutral	_
103-9	17165-17169	with	_
103-10	17170-17176	regard	_
103-11	17177-17179	to	_
103-12	17180-17194	jurisdictional	_
103-13	17195-17201	claims	_
103-14	17202-17204	in	_
103-15	17205-17214	published	_
103-16	17215-17219	maps	_
103-17	17220-17223	and	_
103-18	17224-17237	institutional	_
103-19	17238-17250	affiliations	_
103-20	17251-17252	.	_

